<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84077</article-id><article-id pub-id-type="doi">10.7554/eLife.84077</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Vitamin B2 enables regulation of fasting glucose availability</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-323541"><name><surname>Masschelin</surname><given-names>Peter M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33404"><name><surname>Saha</surname><given-names>Pradip</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295803"><name><surname>Ochsner</surname><given-names>Scott A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253201"><name><surname>Cox</surname><given-names>Aaron R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295804"><name><surname>Kim</surname><given-names>Kang Ho</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295805"><name><surname>Felix</surname><given-names>Jessica B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295806"><name><surname>Sharp</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295807"><name><surname>Li</surname><given-names>Xin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7325-4250</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-248831"><name><surname>Tan</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295808"><name><surname>Park</surname><given-names>Jun Hyoung</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295809"><name><surname>Wang</surname><given-names>Liping</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3537-0952</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295810"><name><surname>Putluri</surname><given-names>Vasanta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-248837"><name><surname>Lorenzi</surname><given-names>Philip L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0385-7774</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295811"><name><surname>Nuotio-Antar</surname><given-names>Alli M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1830-4868</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127273"><name><surname>Sun</surname><given-names>Zheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6858-0633</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35812"><name><surname>Kaipparettu</surname><given-names>Benny Abraham</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71178"><name><surname>Putluri</surname><given-names>Nagireddy</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246176"><name><surname>Moore</surname><given-names>David D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-162286"><name><surname>Summers</surname><given-names>Scott A</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-295813"><name><surname>McKenna</surname><given-names>Neil J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-17611"><name><surname>Hartig</surname><given-names>Sean M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2695-2072</contrib-id><email>hartig@bcm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Medicine, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Molecular and Cellular Biology, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00q16t150</institution-id><institution>Department of Anesthesiology, University of Texas Health Sciences Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Nutrition and Integrative Physiology, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Pediatrics, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an7q238</institution-id><institution>Department of Nutritional Sciences and Toxicology, University of California, Berkeley</institution></institution-wrap><addr-line><named-content content-type="city">Berkeley</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tontonoz</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>James</surname><given-names>David E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0384j8v12</institution-id><institution>University of Sydney</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>07</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84077</elocation-id><history><date date-type="received" iso-8601-date="2022-10-10"><day>10</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-06-24"><day>24</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-10-18"><day>18</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.16.512439"/></event></pub-history><permissions><copyright-statement>© 2023, Masschelin et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Masschelin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84077-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84077-figures-v1.pdf"/><abstract><p>Flavin adenine dinucleotide (FAD) interacts with flavoproteins to mediate oxidation-reduction reactions required for cellular energy demands. Not surprisingly, mutations that alter FAD binding to flavoproteins cause rare inborn errors of metabolism (IEMs) that disrupt liver function and render fasting intolerance, hepatic steatosis, and lipodystrophy. In our study, depleting FAD pools in mice with a vitamin B2-deficient diet (B2D) caused phenotypes associated with organic acidemias and other IEMs, including reduced body weight, hypoglycemia, and fatty liver disease. Integrated discovery approaches revealed B2D tempered fasting activation of target genes for the nuclear receptor PPARα, including those required for gluconeogenesis. We also found PPARα knockdown in the liver recapitulated B2D effects on glucose excursion and fatty liver disease in mice. Finally, treatment with the PPARα agonist fenofibrate activated the integrated stress response and refilled amino acid substrates to rescue fasting glucose availability and overcome B2D phenotypes. These findings identify metabolic responses to FAD availability and nominate strategies for the management of organic acidemias and other rare IEMs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>nuclear receptor</kwd><kwd>FAD</kwd><kwd>inborn errors of metabolism</kwd><kwd>gluconeogenesis</kwd><kwd>metabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000041</institution-id><institution>American Diabetes Association</institution></institution-wrap></funding-source><award-id>1-18-IBS-105</award-id><principal-award-recipient><name><surname>Hartig</surname><given-names>Sean M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK114356</award-id><principal-award-recipient><name><surname>Hartig</surname><given-names>Sean M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The dietary vitamin riboflavin provides the chemical backbone to generate essential substrates that support liver glucose metabolism during low-nutrient conditions.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) serve as essential cofactors for diverse proteins that mediate oxidation-reduction (redox) reactions, transcriptional regulation, and metabolism (<xref ref-type="bibr" rid="bib44">Powers, 2003</xref>). In particular, FAD supports the activity of flavoproteins that enable the electron transport chain (ETC), the tricarboxylic acid (TCA) cycle, and fatty acid oxidation (FAO). Along these lines, mutations occurring in more than 50% of human flavoproteins cause inborn errors of metabolism (IEMs) with heterogeneous clinical presentations frequently characterized by organic acidemia, fasting intolerance, and fatty liver disease (<xref ref-type="bibr" rid="bib4">Balasubramaniam et al., 2019</xref>). Compared to the more well-understood roles of nicotinamide adenine dinucleotide (NAD), the physiological relevance of FAD has remained largely ignored. This gap in knowledge slows the pursuit of therapeutic strategies to treat IEM and leaves fundamental energy balance roles for FAD unresolved.</p><p>The liver coordinates whole-body metabolism during fasting by releasing glucose and other fuels to spare the brain and survive low-nutrient conditions. Nuclear receptors sense and receive the signals of nutrient abundance in the liver to perform precise regulation of genes that ultimately maintain the energetic needs of the FAO and amino acid catabolism pathways serving gluconeogenesis (<xref ref-type="bibr" rid="bib54">Scholtes and Giguère, 2022</xref>). Among nuclear receptors, peroxisome proliferator-activated receptor a (PPARα) modulates fasting responses and pivots hepatocytes toward conservation and recycled substrates to sustain energy production. NAD can activate nuclear receptor co-activators in the liver for gluconeogenesis (<xref ref-type="bibr" rid="bib50">Rodgers et al., 2005</xref>). However, the role of FAD as a bridging molecule for metabolic reactions and transcriptional regulation of energy balance are almost completely unknown. Synthetic PPARα agonists promote FAO by directing the activity of pathways for balanced lipid metabolism in the liver, which consequently supported a series of FDA-approved fibrate drugs for the treatment of hypertriglyceridemia (<xref ref-type="bibr" rid="bib24">Jackevicius et al., 2011</xref>). The lipid-lowering properties of bezafibrate and fenofibrate motivated preclinical studies (<xref ref-type="bibr" rid="bib63">Steele et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Waskowicz et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Yavarow et al., 2020</xref>) that form ongoing efforts to overcome the limited armament of therapies for IEMs.</p><p>Nutrition impacts FAD availability for the organism and dietary riboflavin (vitamin B2) supplies the backbone for all FAD and FMN synthesis. Riboflavin deficiency gives rise to abnormal development and energy balance disorders. Low riboflavin also occurs in more broadly observed diseases including cancer (<xref ref-type="bibr" rid="bib26">Kabat et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Powers, 2005</xref>), HIV (<xref ref-type="bibr" rid="bib5">Beach et al., 1992</xref>; <xref ref-type="bibr" rid="bib15">Fouty et al., 1998</xref>), and cardiovascular disease (<xref ref-type="bibr" rid="bib65">Tzoulaki et al., 2012</xref>). Thus, models that expand how FAD requirements form the regulatory environment for metabolic homeostasis provide opportunities for preclinical experiments and studies of fundamental nutrient-sensing and disease mechanisms. Here, we define the outcomes of vitamin B2 depletion resembling IEMs of flavoprotein deficiency and transcriptional pathways that preserve glucose availability in fasted mice.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Riboflavin deficiency alters body composition and energy expenditure</title><p>In mammals, diet furnishes vitamin B2 to synthesize all the FAD for electron transfer in the mitochondria and redox reactions required for cellular homeostasis (<xref ref-type="bibr" rid="bib44">Powers, 2003</xref>). Among key metabolic organs, ad libitum FAD levels were highest in the liver, heart, and kidney (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). To study how FAD depletion influences energy balance, we exposed male mice to vitamin B2-deficient (B2D) or control diets for 4 wk and performed metabolic phenotyping (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). We found that 99% B2D was sufficient to reduce liver FAD levels by 70% (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Moreover, B2D significantly blunted weight gain (<xref ref-type="fig" rid="fig1">Figure 1d and e</xref>), and body composition measurements showed B2D also reduced fat mass (<xref ref-type="fig" rid="fig1">Figure 1f</xref>). When we examined the contribution of B2 to energy expenditure, we were surprised the stunted body weight phenotype of B2D did not arise from higher oxygen consumption or canonical markers of brown adipose tissue thermogenesis (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). B2D strongly reduced oxygen consumption (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), but substrate preference was unchanged (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). Animals moved less during nighttime measurements (<xref ref-type="fig" rid="fig1">Figure 1i</xref>). In absolute terms, B2D-fed mice consumed the same amount of food as controls (<xref ref-type="fig" rid="fig1">Figure 1j</xref>). Female mice exposed to B2D also showed reduced body weight gain and locomotory activity with trends toward lower oxygen consumption in the night phase (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). In contrast to B2D, reducing riboflavin in the diet by 90% did not impact liver FAD levels nor influence energy balance (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). These results identify B2 requirements that make FAD available for energy expenditure requirements and body weight in male and female mice.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Riboflavin deficiency alters body composition and energy expenditure.</title><p>(<bold>a</bold>) Ad libitum flavin adenine dinucleotide (FAD) concentrations measured from male WT mice (n = 3). (<bold>b</bold>) One-month-old male mice (n = 5 per group) were exposed to 99% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 1 mo, followed by metabolic phenotyping. (<bold>c</bold>) FAD concentrations in the fasted liver. (<bold>d</bold>) Body weight (g), (<bold>e</bold>) % body weight gain and (<bold>f</bold>) body composition (% of body mass). Mice were individually housed and monitored in CLAMS-HC. (<bold>g</bold>) Recorded traces of oxygen consumption (VO<sub>2</sub>), (<bold>h</bold>) respiratory exchange ratio (RER), (<bold>i</bold>) locomotor activity, and (<bold>j</bold>) cumulative food intake during dark (gray) and light (white) periods in the metabolic cages. One-way ANOVA with Sidak multiple-comparison tests was used for (<bold>a</bold>). Liver, heart, and kidney show statistically higher FAD levels versus other tissues. Other statistical analyses include two-way ANOVA with Sidak multiple-comparison tests for body weight (<bold>d, e</bold>) and body composition (fat and lean mass%) by Mann–Whitney for Ctrl v. B2D (<bold>f</bold>). Statistical analysis of CLAMS data was performed by ANCOVA with lean body mass as a co-variate (<bold>g–j</bold>). Data are represented as mean ± SEM. #p&lt;0.10, *p&lt;0.05, **p&lt;0.02. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Effects of 99% riboflavin deficiency on brown adipose tissue (BAT) in male and female mice.</title><p>Analysis of BAT gene expression and tissue morphology (H/E) for (<bold>a</bold>) male and (<bold>b</bold>) female mice fed 99% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 4 wk. Scale bar is 50 μm for BAT morphology. <italic>Tbp</italic> served as the invariant control for gene expression measurements. Statistical analysis of gene expression was performed by Mann–Whitney test for (<bold>a</bold>) and (<bold>b</bold>). Data are represented as mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Metabolic effects of 99% riboflavin deficiency in female mice.</title><p>One-month-old female mice (n = 5 per group) were exposed to 99% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 1 mo, followed by metabolic phenotyping. (<bold>a</bold>) Flavin adenine dinucleotide (FAD) concentrations in the fasted liver. (<bold>b</bold>) Body weight (g), (<bold>c</bold>) % body weight gain and (<bold>d</bold>) body composition (% of body mass). Mice were individually housed and monitored in CLAMS-HC. (<bold>e</bold>) Recorded traces of oxygen consumption (VO<sub>2</sub>), (<bold>f</bold>) Respiratory exchange ratio (RER), (<bold>g</bold>) locomotor activity, and (<bold>h</bold>) cumulative food intake during dark (gray) and light (white) periods in the metabolic cages. Statistical analyses are Mann–Whitney test (<bold>a</bold>), two-way ANOVA with Sidak multiple-comparison tests (<bold>b, c</bold>), body composition (fat and lean mass%) by Mann-Whitney for Ctrl vs. B2D (<bold>d</bold>), CLAMS by ANCOVA with lean body mass as a co-variate (<bold>e–h</bold>). Data are represented as mean ± SEM. #p&lt;0.10. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig1s2sdata1">Figure 1—figure supplement 2—source data 1</xref>.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig1-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Metabolic effects of 90% riboflavin deficiency in mice.</title><p>One-month-old male mice (n = 5 per group) were exposed to 90% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 1 mo, followed by metabolic phenotyping. (<bold>a</bold>) Flavin adenine dinucleotide (FAD) concentrations in the fasted liver. (<bold>b</bold>) Body weight (g), (<bold>c</bold>) % body weight gain and (<bold>d</bold>) body composition (% of body mass). (<bold>e</bold>) Blood glucose excursion in 90% B2D or Ctrl mice during pyruvate tolerance tests (n = 5). Mice were individually housed and monitored in CLAMS-HC. (<bold>f</bold>) Recorded traces of oxygen consumption (VO<sub>2</sub>), (<bold>g</bold>) Respiratory exchange ratio (RER), (<bold>h</bold>) locomotor activity, and (<bold>i</bold>) cumulative food intake during dark (gray) and light (white) periods in the metabolic cages. Statistical analyses are body weight by two-way ANOVA with Sidak multiple-comparison tests (<bold>b, c</bold>), body composition (fat and lean mass%) by Mann–Whitney for Ctrl vs. 90%B2D, pyruvate tolerance test (<bold>e</bold>) by two-way ANOVA with Sidak multiple-comparison tests and area under the curve (AUC) by Mann–Whitney test, CLAMS by ANCOVA with lean body mass as a co-variate (<bold>f–i</bold>). Data are represented as mean ± SEM. *p&lt;0.05. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig1s3sdata1">Figure 1—figure supplement 3—source data 1</xref>.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig1-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig1-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>FAD is required for hepatic glucose production during fasting</title><p>Common clinical phenotypes of flavoprotein and nutritional riboflavin depletion disorders include fasting intolerance and hypoglycemia derived from impaired liver glucose production and metabolic flexibility (<xref ref-type="bibr" rid="bib21">Houten et al., 2016</xref>). We found that liver FAD displayed circadian accumulation (<xref ref-type="bibr" rid="bib43">Patel et al., 2012</xref>) coinciding with the onset of gluconeogenesis (ZT12) that occurs before the active period for mice (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Follow-up experiments also demonstrated re-feeding mice after 16 hr of fasting raised blood glucose levels (<xref ref-type="fig" rid="fig2">Figure 2b</xref>), but depleted liver FAD concentrations (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). We next sought to understand whether the changes in FAD that occur in the mouse liver during B2D affected gluconeogenesis using multiple in vivo methods. After 4 wk of B2D, we subjected mice to a pyruvate tolerance test (PTT) after an overnight fast. Consistent with impaired gluconeogenesis from pyruvate, blood glucose concentrations were lower in B2D conditions compared with control diets at all times during the PTT (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). Further plasma analysis established trends toward higher fasting concentrations of lactate, triglycerides (TG), free fatty acids (FFAs), and ketone bodies (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). To further determine the effects of B2D on gluconeogenesis in vivo, we measured basal liver glucose production using an intravenous infusion of radiolabeled glucose in awake mice (<xref ref-type="bibr" rid="bib11">Chopra et al., 2008</xref>; <xref ref-type="bibr" rid="bib52">Saha et al., 2004</xref>). In a liver-specific way, B2D suppressed in vivo hepatic basal glucose production inferred from <sup>3</sup>H-glucose infusions into fasted mice (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Steady-state basal glucose production rates were reached within 1 hr of infusion (<xref ref-type="fig" rid="fig2">Figure 2e’</xref>) and B2D reduced average rates by more than 50% (<xref ref-type="fig" rid="fig2">Figure 2e”</xref>). These data indicate that FAD depletion directly affects liver glucose metabolism.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Liver glucose production requires bioavailable riboflavin.</title><p>(<bold>a</bold>) Liver flavin adenine dinucleotide (FAD) and glucose levels across light/dark cycles (Zeitgeber Time, ZT) in male mice. Overnight (16 hr) fasting and re-fed (6 hr) (<bold>b</bold>) blood glucose and (<bold>c</bold>) liver FAD levels from male WT mice (n = 4). (<bold>d</bold>) Blood glucose excursion during pyruvate tolerance tests (n = 5 per group). (<bold>e</bold>) Basal glucose production was measured in fasted (18 hr) conscious mice (n = 5 vitamin B2-deficient diet [B2D] or n = 7 Ctrl) using constant rate of intravenous infusion (0.1 uCi/min) of [3-<sup>3</sup>H]-glucose using a through a surgically implanted catheter in jugular vein. Whole-body basal glucose production rates (mg/kg/min) were calculated by dividing the [3-<sup>3</sup>H] glucose infusion rate by the plasma glucose-specific activity corrected to the body weight. (<bold>e’</bold>) Steady-state rates were reached within 1 hr of infusion. (<bold>e’’</bold>) Basal hepatic glucose production averaged across the three sampling times. (<bold>f</bold>) RNA-seq coupled with Panther Gene Ontology analysis identified pathways altered by B2D in the liver (n = 5 independent animals/diet). (<bold>g</bold>) Volcano plot depicting expression levels of flavoprotein genes (yellow) after B2D compared to control. (<bold>h</bold>) Lipidomic analysis of Ctrl and B2D (n = 5 per group). This analysis identified triglycerides significantly (p&lt;0.05) increased in B2D versus Ctrl fed mice. (<bold>i</bold>) Representative Oil-Red-O stained liver sections from B2D or Ctrl. Scale bar 50 μm. (<bold>j</bold>) Enrichment of nodes encoded by genes that map to Mouse Genome Informatics (MGI) hypertriglyceridemia phenotypes among nodes with significant HCT intersections with B2D-induced genes. (<bold>k</bold>) Overlap of B2D-enriched nodes with nodes enriched in the human non-alcoholic fatty liver disease (NAFLD) gene expression consensome. The human NAFLD gene expression consensome ranks 18,162 genes based on their discovery across publicly archived clinical NAFLD case/control transcriptomic datasets. Statistical significance (*p&lt;0.05) calculated by Mann–Whitney (<bold>b, c, e”</bold>) or two-way ANOVA with Sidak multiple-comparison test (<bold>d, e’</bold>). Statistical enrichment shown by hypergeometric test for (<bold>j, k</bold>). Data are represented as mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. Serum parameters in and liver lipid measurements are provided in <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref> and <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>, respectively.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Serum parameters in vitamin B2-deficient diet (B2D) interventions.</title><p>Data are mean ± SEM. The number of animals in each group is indicated in parentheses. Statistical significance (p) was determined by Mann-Whitney tests.</p></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-84077-fig2-data2-v1.docx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Liver triglycerides and cholesterol in vitamin B2-deficient diet (B2D) interventions.</title><p>Data are mean ± SEM. The number of animals in each group is indicated in parentheses. Statistical significance (p) was determined by Mann–Whitney tests.</p></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-84077-fig2-data3-v1.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig2-v1.tif"/></fig><p>To explore molecular outcomes of riboflavin depletion, we used RNA-seq to identify biologically cohesive gene programs of B2D in the liver. Consistent with known roles of FAD in FAO, pathways related to fatty acid catabolism and lipid oxidation were strongly repressed in response to B2D (<xref ref-type="fig" rid="fig2">Figure 2f</xref>). Among the B2D-repressed genes annotated to the GO fatty acid catabolism pathway, we noted several encoded flavoproteins whose loss-of-function cause rare organic acidemias, including <italic>Sqor</italic> (<xref ref-type="bibr" rid="bib16">Friederich et al., 2020</xref>) and <italic>Ivd</italic> (<xref ref-type="bibr" rid="bib67">Vockley and Ensenauer, 2006</xref>). To further investigate the effect of B2D on flavoprotein gene expression, we curated a set of 117 genes encoding flavoproteins that require FAD or FMN for activity. Reflecting a specific impact of riboflavin deficiency, flavoprotein genes were enriched among B2D-repressed genes (<xref ref-type="fig" rid="fig2">Figure 2g</xref>) but not B2D-induced genes.</p><p>IEMs that arise from mutations in genes encoding mitochondria FAD transfer enzymes for FAO are identified by elevated organic acids in the blood, lipodystrophy, and fatty liver disease (<xref ref-type="bibr" rid="bib4">Balasubramaniam et al., 2019</xref>). Lipidomics analysis in the liver identified phospholipid (phosphatidylethanolamine [PE], phosphatidylcholine [PC], and lyso-PC) and diacylglycerol (DG) as robustly attenuated (<xref ref-type="fig" rid="fig2">Figure 2h</xref>) in B2D-exposed mice compared to controls. Hepatic steatosis (<xref ref-type="fig" rid="fig2">Figure 2i</xref>) also accompanied B2D effects, presumably due to increased TG (<xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). Accordingly, we hypothesized that altered expression of genes in the liver of B2D relative to normal diet controls reflected non-alcoholic fatty liver disease (NAFLD). To test this hypothesis, we performed high-confidence transcriptional target (HCT) intersection analysis (<xref ref-type="bibr" rid="bib39">Ochsner et al., 2019</xref>) to identify signaling nodes with significant regulatory footprints among liver B2D-induced or -repressed genes. We validated the HCT footprint of B2D against mouse genes from the International Mouse Phenotyping Consortium, whose knockout increased liver TG (<xref ref-type="fig" rid="fig2">Figure 2j</xref>). From this approach, we identified strong enrichment of genes induced by B2D with metabolic transcription factor knockouts that cause fatty liver disease, such as <italic>Ppara</italic> (<xref ref-type="bibr" rid="bib12">Cotter et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">Kersten et al., 1999</xref>; <xref ref-type="bibr" rid="bib36">Montagner et al., 2016</xref>), <italic>Nr1h4</italic> (<xref ref-type="bibr" rid="bib61">Sinal et al., 2000</xref>), and <italic>Nr0b2</italic> (<xref ref-type="bibr" rid="bib22">Huang et al., 2007</xref>). Using other computational approaches to expand upon the underpinnings of macrosteatosis caused by B2D, we retrieved nodes previously shown to contain significant transcriptional footprints within genes differentially expressed in clinical NAFLD (<xref ref-type="bibr" rid="bib7">Bissig-Choisat et al., 2021</xref>). B2D-induced genes consisted of footprints for transcription factor nodes active in NAFLD (<xref ref-type="fig" rid="fig2">Figure 2k</xref>), including HNF family members (<xref ref-type="bibr" rid="bib72">Xu et al., 2021</xref>) and SREBP1 (<xref ref-type="bibr" rid="bib59">Shimano et al., 1997</xref>). Collectively, our unbiased approach converged metabolic phenotypes and regulatory networks of B2D with those driving NAFLD and macrosteatosis observed in organic acidemias.</p></sec><sec id="s2-3"><title>PPARα activity maintains liver FAD pools for fasting glucose availability</title><p>Analysis of RNA-seq and ChIP-seq data (<xref ref-type="bibr" rid="bib33">Lee et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Oshida et al., 2015</xref>) discovered strongly enriched PPARα binding near promoter regions for 43 out of 121 putative flavoproteins (p=1.19 × 10<sup>–11</sup>, hypergeometric test) and supported direct coupling of FAD availability and nuclear receptor activity in the liver. Using DNA motif analysis, we also found canonical PPARα target genes among the genes downregulated by B2D (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Likewise, we identified a set of BioGRID-curated interaction partners of PPARα that was enriched among nodes with strong footprints in B2D-repressed genes (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Furthermore, B2D reduced PPARα-regulated flavoprotein genes (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). The observation that patterns of B2D-sensitive gene expression in the liver overlap with PPARα regulatory footprints indicated a convergent role for PPARα and riboflavin in the transcriptional control of gluconeogenic responses.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Liver PPARα governs glucogenic responses to dietary riboflavin.</title><p>(<bold>a</bold>) Top enriched, vitamin B2-deficient diet (B2D) repressed gene sets using the EnrichR transcription factor collection (left). Scatterplot showing enrichment of known BioGRID-curated PPARα interacting nodes (yellow) among nodes with the most significant intersections with B2D-repressed genes (right). (<bold>b</bold>) Volcano plot depicting expression levels of PPARα-regulated flavoprotein genes (yellow) after Ctrl or B2D. (<bold>c</bold>) One-month-old <italic>Ppara<sup>flox/flox</sup></italic> male mice (n = 4–5 per group) received either AAV-TBG-GFP or AAV-TBG-Cre. Two weeks later, mice were provided 99% B2D or isocaloric diet (Ctrl) for 1 mo. (<bold>d</bold>) Body weight (g), (<bold>e</bold>) % body weight gain and (<bold>f</bold>) body composition (% of body mass). (<bold>g</bold>) Blood glucose levels and (<bold>h</bold>) area under the curve (AUC) during pyruvate tolerance tests. (<bold>i</bold>) Representative Oil-Red-O stained liver sections after B2D, scale bar 100 μm. (<bold>j</bold>) Flavin adenine dinucleotide (FAD) concentrations in the fasted liver after 4 wk of B2D. (<bold>k</bold>) Relative mRNA expression of <italic>Ppara</italic> and <italic>Acox1. Tbp</italic> served as the invariant control. (<bold>l</bold>) HepG2 cells were transiently transfected with a PPARα expression plasmid. PPRE luciferase reporter activity was measured in response to PPARα agonist (WY-14643) ± lumiflavin and normalized to β-galactosidase (n = 4). Statistics: *p&lt;0.05 vs. control GFP (<bold>a</bold>, B2D GFP; <bold>b</bold>, B2D Cre; <bold>c</bold>, Ctrl Cre) by two-way ANOVA with Fisher LSD (<bold>d, e, g</bold>), *p&lt;0.05 for body composition (fat and lean mass%) by Mann–Whitney vs. control GFP, *p&lt;0.05, #p&lt;0.10 vs. control GFP by one-way ANOVA with Dunnet’s test and Fisher LSD (<bold>h, j, k</bold>). *p&lt;0.05 by two-way ANOVA with Tukey’s multiple-comparison test for (<bold>l</bold>), a and b are statistical differences vs. vehicle and WY-14643, respectively. Statistical enrichment shown by hypergeometric test (<bold>a</bold>, right, <bold>b</bold>). Data are mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>Ppara</italic> whole-body knockout responses to dietary riboflavin depletion.</title><p>(<bold>a</bold>) One-month-old <italic>Ppara</italic><sup>-/-</sup> male mice (n = 4 per group) were exposed to 99% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 1 mo. (<bold>b</bold>) Body weight (g), (<bold>c</bold>) % body weight gain and (<bold>d</bold>) blood glucose levels during pyruvate tolerance tests. Statistical analysis of phenotypes was analyzed by two-way ANOVA with Sidak multiple-comparison tests (<bold>b–d</bold>). Data are represented as mean ± SEM. *p&lt;0.05. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig3s1sdata1">Figure 3—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig3-figsupp1-v1.tif"/></fig></fig-group><p>To explore the physiological intersections between PPARα and B2D, we deleted <italic>Ppara</italic> in the liver by administering adeno-associated virus (AAV) expressing either Cre recombinase or a GFP under a liver-specific promoter to mice (AAV-TBG-Cre or AAV-TBG-GFP, respectively) harboring a floxed <italic>Ppara</italic> allele (<italic>Ppara<sup>flox/flox</sup></italic>). Cre-mediated excision of the loxP sites depletes <italic>Ppara</italic> in adult mice (<italic>Ppara ΔHep</italic>) and allows us to determine how PPARα mediates B2D responses in mice (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). During 4 wk of diet intervention, <italic>Ppara ΔHep</italic> showed modest body weight gain that was slightly greater than B2D in magnitude. Combined B2D and knockdown of <italic>Ppara</italic> completely abolished body weight gain (<xref ref-type="fig" rid="fig3">Figure 3d and e</xref>) and reduced fat mass (<xref ref-type="fig" rid="fig3">Figure 3f</xref>) relative to control diet conditions. We also learned <italic>Ppara ΔHep</italic> largely recapitulated B2D effects on blood glucose excursion curves during PTTs (<xref ref-type="fig" rid="fig3">Figure 3g and h</xref>). Consistent with previous studies (<xref ref-type="bibr" rid="bib62">Stec et al., 2019</xref>), <italic>Ppara ΔHep</italic> showed greater fat accumulation in the liver relative to <italic>Ppara<sup>flox/flox</sup></italic> on control diet. B2D strongly increased liver lipid across genotypes (<xref ref-type="fig" rid="fig3">Figure 3i</xref>), demonstrating parallel effects of B2D and <italic>Ppara ΔHep</italic> on liver energy balance. Additionally, FAD levels were lowered to similar extents by <italic>Ppara ΔHep</italic> or B2D relative to <italic>Ppara<sup>flox/flox</sup></italic> on control diet (<xref ref-type="fig" rid="fig3">Figure 3j</xref>). We also phenotyped male <italic>Ppara</italic> whole-body knockout (pKO) mice exposed to control or B2D for 1 mo (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). As expected (<xref ref-type="bibr" rid="bib12">Cotter et al., 2014</xref>), we learned pKO largely negated effects of B2D on body weight gain. PTT demonstrated B2D and pKO decreased the conversion of glucose release relative to control diets and wild-type controls.</p><p>To extend our studies of gene regulation, we profiled <italic>Ppara</italic> and the PPARα target gene <italic>Acox1. Ppara</italic> levels were reduced in <italic>Ppara ΔHep</italic>, along with <italic>Acox1</italic> (<xref ref-type="fig" rid="fig3">Figure 3k</xref>). Furthermore, the blunted expression levels of <italic>Acox1</italic> to diet and genetic interventions (<italic>Ppara ΔHep</italic>) confirm B2D confers diminished PPARα activity in the mouse liver. In a complementary approach, we performed experiments to determine how FAD depletion affects PPARα transcriptional activity using the riboflavin analog and competitive inhibitor lumiflavin (<xref ref-type="fig" rid="fig3">Figure 3l</xref>). We found lumiflavin reduced PPRE-luciferase activity in the presence of the PPARA agonist WY-14643, suggesting intact FAD pools contribute to PPARα transcriptional activity. Altogether, these findings suggest that PPARα sustains FAD levels and requires riboflavin to direct glucogenic responses in the liver.</p></sec><sec id="s2-4"><title>PPARα activation by fenofibrate rescues liver glucose production even when FAD cannot be generated from diet</title><p>The FDA-approved fibrate drugs act selectively on PPARα to lower blood lipids and treat hypertriglyceridemia (<xref ref-type="bibr" rid="bib8">Bougarne et al., 2018</xref>). PPARα agonists also show promise for the treatment of some mitochondrial disorders (<xref ref-type="bibr" rid="bib63">Steele et al., 2020</xref>). The convergence of B2D effects on PPARα regulation of gene expression and metabolic responses suggested fenofibrate treatment may restore some metabolic competency in animals on riboflavin-deficient diet. To explore this possibility, we administered fenofibrate after 7 wk of B2D exposure (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). Daily gavage with fenofibrate (300 mg/kg) for 2 wk while maintaining mice on diet interventions significantly reduced body weight gain under B2D conditions (<xref ref-type="fig" rid="fig4">Figure 4b and c</xref>). At the end of the experiment, fasted mice received fenofibrate 2 hr before blood glucose measurements. Fenofibrate increased blood glucose in both groups of mice far above pre-gavage levels (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). When liver histology was examined, we did not detect hepatic steatosis in B2D mice that received fenofibrate (<xref ref-type="fig" rid="fig4">Figure 4e</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Remnant PPARα activation rescues fasting responses impaired by vitamin B2-deficient diet (B2D).</title><p>(<bold>a</bold>) One-month-old male mice (n = 10 per group) were exposed to 99% vitamin B2-deficient diet (B2D) or isocaloric control diet (Ctrl) for 9 wk. For weeks 7–9, mice were gavaged daily with fenofibrate (FF). (<bold>b</bold>) Body weight (g) and (<bold>c</bold>) body weight gain during treatments. For post-gavage (week 9), mice were fasted overnight and administered FF 2 hr before measurements. (<bold>d</bold>) Overnight fasting blood glucose levels for pre-gavage (gray) and after 2 wk of FF treatment (orange). (<bold>e</bold>) Representative H&amp;E-stained liver sections from Ctrl or B2D mice following FF treatment. Scale, 100 μm. (<bold>f</bold>) Expression level of flavoprotein genes in B2D-fed mice following FF. (<bold>g</bold>) Enrichment of B2D+FF with gene footprints repressed in human NAFLD. Statistical analyses include two-way ANOVA with Sidak multiple-comparison test (<bold>b–d</bold>) and *p&lt;0.05 for (<bold>b, c</bold>). *p&lt;0.05 pre-gavage Ctrl vs. B2D or **p&lt;0.05 post-gavage vs. pre-gavage were p-value cutoffs for (<bold>d</bold>). Statistical enrichment shown by hypergeometric test (<bold>f, g</bold>). Data are represented as mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig4-v1.tif"/></fig><p>Given the ability of PPARα to regulate flavoprotein gene expression, we pursued additional RNA-Seq studies to understand the mechanisms that allowed fenofibrate to rescue hypoglycemia in B2D. Consistent with restoration of the flavoprotein transcriptome in response to PPARα activation, we found the number of flavoprotein genes induced by B2D+ fenofibrate more than doubled when compared to B2D alone (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). Given the improvement in hepatic steatosis after PPARα activation, we hypothesized the B2D+ fenofibrate treatment caused inversion of the alignments between B2D and NAFLD transcription networks. Using this approach, we found gene footprints enriched by B2D+ fenofibrate and those depleted in clinical NAFLD converged (<xref ref-type="fig" rid="fig4">Figure 4g</xref>), including the GABP transcriptional program inactivated in inflammatory liver diseases (<xref ref-type="bibr" rid="bib38">Niopek et al., 2017</xref>). These unbiased approaches strengthen the notion that PPARα activation overcomes fatty liver and hypoglycemia phenotypes imposed by B2D.</p></sec><sec id="s2-5"><title>Altered sphingolipid pools and respiratory chain efficiency in B2D</title><p>Fat and protein metabolism produces substrates for the synthesis of sphingolipids, such as ceramides and dihydroceramides, whose tissue accrual associates with severity of fatty liver disease (<xref ref-type="bibr" rid="bib34">Luukkonen et al., 2016</xref>) and mitochondrial dysfunction (<xref ref-type="bibr" rid="bib19">Hammerschmidt et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Park et al., 2016</xref>). To determine whether B2D or B2D+ fenofibrate also changed the sphingolipid composition of the mouse liver, we measured a battery of sphingolipids and detected varying levels of multiple species altered by diet and fenofibrate treatments (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Pool sizes for deoxysphingolipids that require alanine condensation with palmitoyl-CoA trended higher with B2D (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). This finding may derive from the serine availability during hypoxic stress and higher NADH levels (<xref ref-type="bibr" rid="bib74">Yang et al., 2020</xref>). Consistent with this idea, B2D conditions reduced the NAD/NADH ratio in the liver (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). Notably, deoxysphingolipids impair mitochondrial function (<xref ref-type="bibr" rid="bib1">Alecu et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Muthusamy et al., 2020</xref>) and lead to an energy deficit, especially in the liver, where fasting requires elevated demand for biomass.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Fenofibrate impacts mitochondrial respiratory chain efficiency but does not rescue flavin adenine dinucleotide (FAD) levels in vitamin B2-deficient diet (B2D).</title><p>(<bold>a</bold>) Fasting liver sphingolipid species (pmol/mg protein) and pool sizes by mass spectrometry (n = 4 per group). (<bold>b</bold>) Hepatic NAD/NADH ratio. (<bold>c</bold>) Fasting liver FAD and flavin mononucleotide (FMN) relative abundance by mass spectrometry (n = 4 per group). (<bold>d</bold>) Western blot analysis of oxidative phosphorylation complexes. HSP90 served as the invariant control. (<bold>e</bold>) Ratio of oxidized and reduced liver coenzyme Q10 and Q9 by mass spectrometry (n = 4 per group). Statistics are Mann–Whitney test for Ctrl vs. B2D (-FF) or Ctrl vs. B2D (+FF) for (<bold>a, b, c, e</bold>). *p&lt;0.05, #p&lt;0.10. Data are represented as mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. Full gel images are provided in <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Full gel images and original image files for western blots in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Vitamin B2-deficient diet (B2D) effects on sphingolipids in the liver.</title><p>Fasting liver sphingolipid and ceramide species (pmol/mg protein) by mass spectrometry (n = 4 per group). Statistics are Mann–Whitney test for Ctrl vs. B2D (-FF) or Ctrl vs. B2D (+FF). *p&lt;0.05. Data are represented as mean ± SEM. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig5s1sdata1">Figure 5—figure supplement 1—source data 1</xref>.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Pathogenic variants in genes for riboflavin transport and metabolism that deplete FAD impair electron transfer from flavoenzymes in the ETC to coenzyme Q<sub>10</sub> and, ultimately, the energy requirements for gluconeogenesis and fasting tolerance (<xref ref-type="bibr" rid="bib47">Rinaldo et al., 2002</xref>). During prolonged fasting, beta-oxidation and proteolysis produce high fluxes of electrons that flow through the ETC. Coenzyme Q<sub>10</sub> collects and converges electron flow on complex III via complex II (oxidizing succinate into fumarate) or complex I. In this way, the coenzyme Q<sub>10</sub> pool accommodates variable electron fluxes and manages the mitochondria redox environment. Analysis of FAD and FMN (<xref ref-type="fig" rid="fig5">Figure 5c</xref>) confirmed fenofibrate was incapable of reconciling cofactor pools and lacked meaningful impacts on relative levels of some oxidative phosphorylation proteins (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). In contrast to the reduced NAD/NADH, we found B2D treatments accumulated oxidized coenzyme Q<sub>10</sub> and rodent-biased coenzyme Q<sub>9</sub> (<xref ref-type="fig" rid="fig5">Figure 5e</xref>), suggesting higher Q/QH<sub>2</sub>, more negative free energy for complexes I/II, and compensation for the defects in mitochondrial energy efficiency associated with B2D (<xref ref-type="bibr" rid="bib53">Satapati et al., 2015</xref>).</p></sec><sec id="s2-6"><title>Fenofibrate activates the integrated stress response in B2D</title><p>We next measured concentrations of carnitines, amino acid, and hydrophilic metabolites in the liver using mass spectroscopy across the B2D experiments. B2D altered the steady-state levels of valine, methionine, phenylalanine, and caused accumulation of short-chain C5 carnitines that reflect incomplete beta-oxidation of fatty acids (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). Upper arms of glucose metabolism (3PG/2PG) showed lower activities coupled with higher lactate and buildup of metabolites above pyruvate oxidation (G3P, PEP). Metaboanalyst (<xref ref-type="bibr" rid="bib41">Pang et al., 2021</xref>) revealed complete removal of dietary riboflavin caused metabolite changes in the liver that enriched for organic acidemias and inborn errors of the TCA cycle (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). Moreover, B2D caused accumulation of oxidized TCA cycle metabolic intermediates, including fumarate, malate, and 2HG. These findings were compatible with gene sets (<xref ref-type="fig" rid="fig6">Figure 6c</xref>) associated with hypoxia and epithelial-mesenchymal transition (<xref ref-type="bibr" rid="bib55">Sciacovelli et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Ward et al., 2010</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Integrated stress response (ISR) activity forms the basis to reconcile flavin adenine dinucleotide (FAD) disruption.</title><p>(<bold>a</bold>) Glycolysis, tricarboxylic acid (TCA), amino acid, fatty acid oxidation (carnitines) metabolites measured by mass spectrometry across vitamin B2-deficient diet (B2D) and FF treatments (shown as Z-score). (<bold>b</bold>) Metaboanalyst integration demonstrates B2D causes organic acidemias. (<bold>c</bold>) RNA-seq coupled with Gene Set Enrichment Analysis (GSEA) identified gene signatures altered by B2D in the liver (n = 5 independent animals/diet). (<bold>d</bold>) Change in glucose levels 30 min after pyruvate injection pre- and post-fenofibrate gavage (n = 5). (<bold>e</bold>) Amino acid, glucose metabolism, and ISR genes in B2D or B2D + FF, shown as Z-score from RNA-seq data. (<bold>f</bold>) Western blot analysis for ISR proteins in liver lysates from mice treated with B2D (4 wk total) or B2D+FF (9 wk total) and fasted overnight. (<bold>g</bold>) B2D + FF activates the ISR, increasing amino acids that restore glucose availability. Statistical significance was assessed by Mann–Whitney (<bold>a, e</bold>) and two-way ANOVA and Fisher LSD (<bold>d</bold>). Data are represented as mean ± SEM. *p&lt;0.05, #p&lt;0.10. Numerical data for individual panels are provided in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>. Full gel images are provided in <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Numerical data presented in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p>Excel spreadsheet containing raw data for panels presented in the figure.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Full gel images and original image files for western blots in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84077-fig6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-fig6-v1.tif"/></fig><p>PPARα activity favors conversion of proteins to provide amino acids as substrates for anabolic processes (<xref ref-type="bibr" rid="bib28">Kersten et al., 2001</xref>). Our phenotyping analysis of fenofibrate suggested alternative carbon sources might supply the substrates to support glucose production during B2D (<xref ref-type="fig" rid="fig4">Figure 4c</xref>), including pyruvate, which recovered blood glucose in B2D to pre-gavage control levels (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). Amino acids, such as alanine and serine, are also significant contributors to de novo synthesis of glucose. In line with this idea, gluconeogenic amino acids (serine, glutamate, histidine, alanine) showed selective and unique accumulation in the combined B2D and fenofibrate treatments (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). Steady-state levels of other anaplerotic amino acids that replenish the TCA cycle (<xref ref-type="fig" rid="fig6">Figure 6a</xref>), isoleucine, and threonine, also increased at the expense of reduced ketosis and β-hydroxybutyrate (<xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). Similarly, B2D+ fenofibrate elevated levels of TCA cycle metabolites citrate and aconitate and increased the fumarate to succinate ratio. Importantly, we noted moderated levels of carnitines enriched in organic acidemias (C5 and C6). These conditions suggest PPARα activation inhibits cataplerosis of TCA cycle intermediates.</p><p>The constellation of phenotypic effects resulting from riboflavin depletion and fenofibrate suggested global shifts in gene expression and metabolism. RNA-seq indicated B2D+ fenofibrate precipitated a response with elements of greater amino acid and glucose metabolism (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). We also observed a gene signature for the integrated stress response (ISR) further supported by increased expression of the master transcription factor regulator <italic>Atf4,</italic> as well as its key target genes (<italic>Psat1</italic>, <italic>Gls</italic>, <italic>Fgf21</italic>, <italic>Gpt2</italic>, <italic>Ddit4</italic>) during combined B2D+ fenofibrate treatments. Mechanistically, ISR activation occurs through phosphorylation of eIF2α and ATF4 translation, which mediates transcription of target genes to resolve the ISR and regain amino acid homeostasis (<xref ref-type="bibr" rid="bib20">Harding et al., 2003</xref>; <xref ref-type="bibr" rid="bib76">Ye et al., 2012</xref>). In line with this idea, B2D+ fenofibrate achieved robust GCN2 expression, eIF2α phosphorylation, and higher ATF4 levels relative to any other treatment (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). Together, our integrated transcription and mass spectrometry analyses favor a model in which PPARα activation precipitates concerted activation of the ISR, which in turn overcomes the fasting intolerance imposed by B2D (<xref ref-type="fig" rid="fig6">Figure 6g</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Results presented here reveal that vitamin B2 provides critical substrates for glucose availability during fasting in mice. Mammals cannot synthesize vitamin B2, so diet remains the only available source of FAD and FMN (<xref ref-type="bibr" rid="bib44">Powers, 2003</xref>). Our results show that 4 wk of 90% B2D did not influence whole-body metabolic phenotypes. Based on data reported by <xref ref-type="bibr" rid="bib14">Fenton and Cowgill, 1947</xref>, mice require about 4 mg riboflavin/kg diet for normal growth. However, mouse chow generally contains almost twice the daily riboflavin requirement (<xref ref-type="bibr" rid="bib2">Anonymous, 1977</xref>). Most tissues store very little of the vitamin as riboflavin. The majority of bioavailable riboflavin is converted to FAD and excess is excreted in urine as FMN (<xref ref-type="bibr" rid="bib48">Rivlin, 1970</xref>). Riboflavin turnover rates in rodents are also relatively slow at approximately 16 d (<xref ref-type="bibr" rid="bib73">Yang and McCormick, 1967</xref>), which underscores sufficient FAD concentrations remain in the liver after 4 wk of 90% B2D. Therefore, the historical literature suggests 10% of the required level of riboflavin may be sufficient for growth and metabolism in the mouse during our 4-week monitoring period.</p><p>Our work sheds light on how the liver copes with severe metabolic crises and the FAO disorders caused by flavoprotein disruption or FAD depletion during prolonged fasting when both beta-oxidation and gluconeogenesis are concomitantly activated. We speculate these FAO disorders rely on conservation responses when the mitochondria are starved of FAD and FMN required for ETC activity. B2D reduces fat stores and slows metabolism for the energy conservation functions that adapt the animal to survive FAD and FMN depletion. Despite lower body weight gain when compared to control diet, B2D causes reduced energy expenditure. IEMs that arise from mutations in genes encoding mitochondrial FAD transfer enzymes for FAO are often identified by ectopic fat distribution and liver disease (<xref ref-type="bibr" rid="bib4">Balasubramaniam et al., 2019</xref>). People with long-chain fatty acid oxidation disorders (LC-FAODs), including mutations in the FAD-dependent protein ACADVL, also show similar energy expenditure phenotypes as B2D. Indeed, energy expenditure is significantly lower among subjects with LC-FAODs compared to the reference population in the National Health and Nutrition Examination Survey (<xref ref-type="bibr" rid="bib13">DeLany et al., 2023</xref>). These observations suggest that responses to B2D are relevant to studying IEMs defined by mutations in FAD-dependent metabolic enzymes.</p><p>Interestingly, the metabolic phenotype of B2D resists conditions unfavorable for mitochondrial function, including hypoxia, suggesting that these changes select for survival. Increased reliance upon glycolysis occurs in mitochondrial disease (<xref ref-type="bibr" rid="bib49">Robinson, 2006</xref>) and hypoxia responses activate glycolytic enzymes that allow energy production when the mitochondria are starved of oxygen as a substrate for oxidative phosphorylation. Likewise, our data support the idea that the stress of B2D gives rise to an environment for fenofibrate and PPARα activation to co-opt the ISR, adapt to TCA cycle dysfunction, and engage hypoxia enzymes to reconcile anaplerosis. Elevated TCA cycle intermediates, such as fumarate, then act to stabilize antioxidant transcription factors and protect against oxidative stress in the liver (<xref ref-type="bibr" rid="bib3">Ashrafian et al., 2012</xref>) during the stress of IEMs modeled in our study.</p><p>IEMs modeled in our study frequently present NAFLD-like phenotypes that contribute to fasting intolerance (<xref ref-type="bibr" rid="bib47">Rinaldo et al., 2002</xref>). In our model, B2D alters lipid profiles and gene expression patterns that converge B2D with more common NAFLD phenotypes. The liver dominates mass-specific metabolic rates (<xref ref-type="bibr" rid="bib51">Rolfe and Brown, 1997</xref>) and, for this reason, the NAFLD caused by B2D likely reflects a combination of lower hepatic fatty acid oxidation contributing to the accumulation of liver triglycerides and other complex lipid species observed in obesity (<xref ref-type="bibr" rid="bib58">Shi et al., 2022</xref>). Our lipidomics also revealed that B2D caused accumulation of deoxysphingolipids, which also become more abundant in NAFLD from incomplete fat oxidation and accrual of toxic intermediates (<xref ref-type="bibr" rid="bib17">Gai et al., 2020</xref>). These findings are particularly relevant for discovering new biomarkers for fatty liver disease.</p><p>The energetic requirements of fasting dictate substrate oxidation and electron transport. B2D restricts mitochondrial function, which causes reductive pressures that likely exacerbate ROS formation in part through proton leak. PPARα activation prevents oxidative stress (<xref ref-type="bibr" rid="bib23">Ip et al., 2004</xref>) by merging lower NAD/NADH and oxidized Q, which, in turn, lowers the free energy of electron transport through complexes I and II. These data are consistent with inhibition of complex II, resulting in a more oxidized Q pool and reveals an important adaptation that allows the liver to overcome riboflavin deficiency (<xref ref-type="bibr" rid="bib64">Treberg et al., 2011</xref>).</p><p>Inefficient amino acid availability, or increased requirements of amino acids to maintain gluconeogenesis, activate ATF4 and the ISR. ATF4 is the principal downstream effector of the ISR, whose regulation becomes altered in human and rodent NAFLD (<xref ref-type="bibr" rid="bib46">Puri et al., 2008</xref>; <xref ref-type="bibr" rid="bib57">Seo et al., 2009</xref>). Integrated metabolomic and RNA-seq studies demonstrated that fenofibrate unveils the ISR to increase the abundance of anaplerotic amino acids. We are unaware of other studies that observe coincident activation of PPARα and ATF4 to drive adaptive responses to liver stress. However, induction of shared PPARα and ATF4 targets, including <italic>Fgf21</italic>, may contribute to hepatoprotection from lipotoxic lipid accumulation (<xref ref-type="bibr" rid="bib36">Montagner et al., 2016</xref>). It will be interesting in the future to determine why B2D exposes a vulnerability to fenofibrate that engages selective genome regulation by PPARα and ATF4 for recovering glucose production in settings of fasting intolerance.</p><p>This study is unique in its comprehensive approach to understand the complex metabolic consequences of FAD depletion and riboflavin auxotrophy in mouse models. Nevertheless, we acknowledge some limitations of the study. While the effect of B2D may act through different pathways and tissues, we demonstrated some of these effects may be mediated through disturbance of nuclear receptor activity and altered glucose availability in the liver. A limitation of our study is that we have focused on how PPARα requires vitamin B2 in the mouse liver to produce glucose, and it is possible that other fasting responsive transcription factors (<xref ref-type="bibr" rid="bib6">Bideyan et al., 2021</xref>) are sensitive to B2D. One important caveat of these experiments is that the kidney also contributes to glucose production during fasting (<xref ref-type="bibr" rid="bib25">Joseph et al., 2000</xref>). Although our in vivo experiments do not explore whether the kidney reconciled any liver gluconeogenic deficiency, our observations reveal fundamental vitamin requirements to source the liver with the FAD and FMN pools necessary for energy balance.</p><p>There is evidence fibrates generate beneficial effects in IEMs, including improvement of antioxidant defenses and resolution of inflammation (<xref ref-type="bibr" rid="bib56">Seminotti et al., 2023</xref>). While further studies are needed, we describe allostatic outcomes of PPARα activation that overcome bioenergetic costs of fasting. Rare diseases of flavoprotein mutations, including organic acidemias, cause substantial morbidity and have no cure. Therefore, understanding how nuclear receptor regulation of flavoprotein function and FAD pool distribution surmounts hypoglycemia and fatty liver is valuable for describing fundamental physiology and implementing future therapeutic strategies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice and housing conditions</title><p>All animal procedures were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine (AN-6411). All mice were housed in a barrier-specific pathogen-free animal facility with 12 hr dark-light cycle and free access to water and food. C57BL/6J wild-type mice (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link>) were obtained from the BCM Center for Comparative Medicine and global <italic>Ppara</italic><sup>-/-</sup> mice (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:008154">IMSR_JAX:008154</ext-link>) were generated previously (<xref ref-type="bibr" rid="bib32">Lee et al., 1995</xref>). In all experiments, male mice were randomly placed on control or riboflavin deficient diet starting at 4 wk of age. Riboflavin-deficient and matched control diets (<xref ref-type="bibr" rid="bib71">Xu et al., 2018</xref>) were provided by Research Diets: 90% control, D10012G; 90% riboflavin-deficient, D12030102; 99% control, A18041301; or 99% riboflavin-deficient, A19080901. All diets were isocaloric, and amino acids were kept constant (<xref ref-type="supplementary-material" rid="supp1">Supplementary files 1 and 2</xref>).</p></sec><sec id="s4-2"><title>AAV TBG administration</title><p>For AAV-TBG injections, 1-month old <italic>Ppara<sup>flox/flox</sup></italic> mice (<xref ref-type="bibr" rid="bib9">Brocker et al., 2017</xref>) were injected with AAV8-TBG-iCre-WPRE (1 × 10<sup>11</sup> vc/ml, Addgene# 192878) or AAV8-TBG-EGFP-WPRE (1 × 10<sup>11</sup> vc/ml, Addgene #192880) into the tail vein in a total volume of 100 μl saline. These viruses were provided by the Gene Vector Core at Baylor College of Medicine. Mice were allowed to recover for 2 wk to permit for viral expression and recombination of floxed <italic>Ppara</italic> alleles before being used for B2D experiments.</p></sec><sec id="s4-3"><title>Fenofibrate gavage</title><p>We used malnutrition (<xref ref-type="bibr" rid="bib66">van Zutphen et al., 2016</xref>), <italic>Ppara</italic> knockout (<xref ref-type="bibr" rid="bib36">Montagner et al., 2016</xref>), and cancer cachexia (<xref ref-type="bibr" rid="bib18">Goncalves et al., 2018</xref>) studies to design fenofibrate interventions. 0.5% methylcellulose solution was prepared by heating 150 ml water with 2.5 g 400 cP methylcellulose (Sigma, #M0262) added with stirring. Chilled water was added (350 ml) and stirred overnight at 4°C. Fenofibrate-gavage solution was made with 112.5 mg fenofibrate (Sigma, #F6020) in 1.5 ml 0.5% methylcellulose solution. Mice were gavaged daily at 300 mg/kg.</p></sec><sec id="s4-4"><title>Pyruvate tolerance test (PTT)</title><p>To determine pyruvate tolerance, mice were fasted for 16 hr, and Na-pyruvate was administered (1 g/kg body weight) by intraperitoneal injection. Blood glucose levels were monitored at 0, 15, 30, 60, and 120 min by a Freestyle Glucose Monitoring System (Abbott Laboratories).</p></sec><sec id="s4-5"><title>Basal glucose production rate in live mice</title><p>Basal glucose production was measured as described previously (<xref ref-type="bibr" rid="bib52">Saha et al., 2004</xref>). In brief, mice were anesthetized, and a midline neck incision was made to expose the jugular vein. A microcannula was inserted into the jugular vein, threaded into the right atrium, and anchored at the venotomy site. Mice were allowed to recover for 4–5 d with ad libitum access to water and food. Following an overnight fast, the conscious mice received a bolus dose (10 uCi) and then a constant rate intravenous infusion (0.1 uCi/min) of chromatography-purified [3-<sup>3</sup>H]-glucose using a syringe infusion pump for 120 min through surgically implanted catheter in jugular vein. For determination of basal glucose production, blood samples were collected after 0, 60, 90, and 120 min of labeled glucose infusion to calculate the basal glucose production rates using plasma glucose-specific activity of tritiated labeled glucose (3-<sup>3</sup>H). Steady states were reached within 1 hr of infusion. Plasma was separated and deproteinized using equal volumes of barium hydroxide and zinc sulfate, dried to remove <sup>3</sup>H<sub>2</sub>O, resuspended in water, and counted in scintillation fluid using a liquid scintillation counter (Beckman Instruments, Palo Alto, CA). We calculated basal whole-body glucose production (mg/kg/min) by dividing the [3-<sup>3</sup>H] glucose infusion rate by the plasma glucose-specific activity corrected to body weight (<xref ref-type="bibr" rid="bib68">Wall et al., 1957</xref>).</p></sec><sec id="s4-6"><title>Indirect calorimetry</title><p>Wild-type mice were maintained on experimental diets and housed at room temperature in Comprehensive Lab Animal Monitoring System Home Cages (CLAMS-HC, Columbus Instruments). Oxygen consumption, CO<sub>2</sub> emission, energy expenditure, food and water intake, and activity were measured for 5 d (BCM Mouse Metabolic and Phenotyping Core). Mouse body composition was examined by magnetic resonance imaging (Echo Medical Systems) before indirect calorimetry.</p></sec><sec id="s4-7"><title>Histology</title><p>Sections of liver tissue were frozen in Tissue-Tek OCT compound (4583; Sakura Finetek USA), and neutral lipids stained with Oil Red O. Formalin-fixed paraffin-embedded tissue sections were stained with hematoxylin and eosin (H/E). Images were captured on a Nikon Ci-L Brightfield microscope.</p></sec><sec id="s4-8"><title>Serum and lipid assays</title><p>Fasted serum was used to measure serum lactate (K607; Biovision), ALT (TR71121; Thermo Scientific), AST (TR70121; Thermo Scientific), beta-hydroxybutyrate (Biovision K632), and serum-free fatty acids (#sfa-1; Zen-Bio).</p></sec><sec id="s4-9"><title>Liver FAD measurements</title><p>10–15 mg of liver tissue was deproteinated (K808; Biovision), followed by measurement of FAD through a colorimetric assay (K357; Biovision). FAD concentration was standardized to input tissue weight.</p></sec><sec id="s4-10"><title>Hepatic TG and cholesterol</title><p>Both serum and tissue samples were analyzed for triglycerides (Triglyceride reagent TR22421; Thermo Scientific) and cholesterol (Total Cholesterol Reagent TR13421; Thermo Scientific). Hepatic TGs and cholesterol were assayed as described previously (<xref ref-type="bibr" rid="bib30">Kim et al., 2019</xref>). Briefly, liver homogenates were mixed with a 1:2 chloroform:methanol solution followed by isolation of the lipid-rich chloroform layer (modified Folch method).</p></sec><sec id="s4-11"><title>Immunoblotting</title><p>Cell and tissue lysates were prepared in Protein Extraction Reagent (Thermo Fisher) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher). Western blotting was performed with whole-cell lysates run on 4–12% Bis-Tris NuPage gels (Life Technologies) and transferred onto Immobilon-P Transfer Membranes (Millipore), followed by antibody incubation. Immunoreactive bands were visualized by chemiluminescence. Antibodies used in this study are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-12"><title>RNA extraction and RNA-seq analysis</title><p>Total liver RNA was extracted using the QIAGEN RNeasy Plus Mini kit (74034; QIAGEN). Sample quality was confirmed on an Agilent 2100 Bioanalyzer (Agilent). mRNA library preparation and RNA sequencing were performed by Novogene. mRNA libraries were prepared with NEBNext Ultra RNA Library Prep Kit for Illumina (NEB) and size selection for libraries was performed using AMPure XP system (Beckman Coulter), followed by library purity analysis. Libraries were sequenced on NovaSeq PE150 and reads mapped to the UCSC mouse reference genome mm10 using STAR. FeatureCounts was used to calculate the expression level as reads per kilobase per million (RPKM). DESeq2 calculated differentially expressed genes with p-values adjusted using Benjamini and Hochberg’s method for controlling the false discovery rate (FDR). Genes with significant differential expression were determined by p&lt;0.05. Gene Set Enrichment Analysis was performed with the Molecular Signatures Database, and -log<sub>10</sub>(p-value) calculated for Hallmark gene sets.</p></sec><sec id="s4-13"><title>qPCR</title><p>cDNA was synthesized from total RNA using qScript (QuantBio #95048-100). Relative mRNA expression was measured with SsoAdvanced Universal Probes Supermix reactions (Bio-Rad #175284) read out with a QuantStudio 3 real-time PCR system (Applied Biosystems). TATA-box binding protein (<italic>Tbp</italic>) was the invariant control. Roche Universal Probe Gene Expression Assays were used as previously described (<xref ref-type="bibr" rid="bib31">Koh et al., 2018</xref>). The following primer and probe sets were used to detect the following genes: <italic>Ppara</italic>: <named-content content-type="sequence">tcgagttcatgcaagtttcg</named-content> (F), <named-content content-type="sequence">tccctcctggcttctctagg</named-content> (R), Roche Universal Probe Library probe #1; <italic>Acox1</italic>: <named-content content-type="sequence">caccattgccattcgataca</named-content> (F), <named-content content-type="sequence">tgcgtctgaaaatccaaaatc</named-content> (R), Roche Universal Probe Library probe #106; <italic>Ucp1:</italic> <named-content content-type="sequence">ggcctctacgactcagtcca</named-content> (F), <named-content content-type="sequence">taagccggctgagatcttgt</named-content> (R), Roche Universal Probe Library probe #34; <italic>Cidea:</italic> <named-content content-type="sequence">aaaccatgaccgaagtagcc</named-content> (F), <named-content content-type="sequence">aggccagttgtgatgactaagac</named-content> (R), Roche Universal Probe Library probe #66; <italic>Prdm16:</italic> <named-content content-type="sequence">acaggcaggctaagaaccag</named-content> (F), <named-content content-type="sequence">cgtggagaggagtgtcttcag</named-content> (R), Roche Universal Probe Library probe #56; <italic>Pparg2:</italic> <named-content content-type="sequence">gaaagacaacggacaaatcacc</named-content> (F), <named-content content-type="sequence">gggggtgatatgtttgaacttg</named-content> (R), Roche Universal Probe Library probe #7; <italic>Cpt1b:</italic> <named-content content-type="sequence">gagtgactggtgggaagaatatg</named-content> (F), <named-content content-type="sequence">gctgcttgcacatttgtgtt</named-content> (R), Roche Universal Probe Library probe #92; <italic>Tbp:</italic> <named-content content-type="sequence">cggtcgcgtcattttctc</named-content> (F), <named-content content-type="sequence">gggttatcttcacacaccatga</named-content> (R), and Roche Universal Probe Library probe #51.</p></sec><sec id="s4-14"><title>Luciferase assays</title><p>We used HepG2 cells purchased directly by our lab for the studies. All cells are tested monthly to ensure an absence of mycoplasma contamination. HepG2 cells (ATCC, HB-8065, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_002">CVCL_002</ext-link>) were maintained in the following media: Eagle’s Minimum Essential Media supplemented with 10% FBS, and 1% penicillin/streptomycin antibiotics. We used Lipofectamine 2000 to transiently express pcDNA3.1-PPARA (Addgene #169019), pCMV β-gal (ATCC) and PPRE-luciferase fusion plasmids (Addgene #1015). 20 hr later, cells were treated with lumiflavin (Cayman) or 10 μM WY14643 (Cayman) for an additional 24 hr. 0.1% DMSO served as the vehicle treatment. Reporter gene activity was detected using the Promega Luciferase Assay Kit. Relative luminescence units were normalized to β-galactosidase activity (Sigma).</p></sec><sec id="s4-15"><title>Consensome and high-confidence transcriptional (HCT) target intersections</title><p>Transcription factor footprint analysis and consensome enrichments were performed (<xref ref-type="bibr" rid="bib39">Ochsner et al., 2019</xref>). For transcription factors, node and node family consensomes are gene lists ranked according to the strength of their regulatory relationship with upstream signaling pathway nodes derived from independent publicly archived transcriptomic or ChIP-Seq datasets. Genes in the 95th percentile of a given node consensome were designated high-confidence transcriptional targets (HCTs) for that node and used as the input for the HCT intersection analysis using the Bioconductor GeneOverlap analysis package implemented in R. For both consensome and HCT intersection analysis, p-values were adjusted for multiple testing using the method of Benjamini and Hochberg to control the FDR as implemented with the p. adjust function in R, to generate q values. Evidence for a transcriptional regulatory relationship between a node and a gene set was inferred from a larger intersection between the gene set and HCTs for a given node or node family than would be expected by chance after FDR correction (q &lt; 0.05). The HCT intersection analysis code has been deposited in the SPP GitHub account at <ext-link ext-link-type="uri" xlink:href="https://github.com/signaling-pathways-project/ominer/">https://github.com/signaling-pathways-project/ominer/</ext-link> (copy archived at <xref ref-type="bibr" rid="bib60">signaling-pathways-project, 2023</xref>).</p></sec><sec id="s4-16"><title>Metabolomics</title><p>Targeted measurements of hepatic carnitines, fatty acids, lipids species, CoAs, glycolysis, and TCA metabolites were carried out by the BCM Dan L Duncan Cancer Center CPRIT Cancer Proteomics and Metabolomics Core. Parallel analysis of lipids and ceramides was performed at the University of Utah. All samples were processed and analyzed as described previously (<xref ref-type="bibr" rid="bib10">Chaurasia et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Kettner et al., 2016</xref>).</p><sec id="s4-16-1"><title>Reagents</title><p>High-performance liquid chromatography grade and mass spectrometry grade reagents were used: acetonitrile, methanol, and water (Burdick &amp; Jackson); formic acid, ammonium acetate, and internal standards (Sigma-Aldrich); MS grade lipid standards (Avanti Polar Lipids).</p></sec><sec id="s4-16-2"><title>Internal standards and quality control</title><p>To assess overall process reproducibility, mouse pooled liver or serum samples were run along with the experimental samples. A number of internal standards, including injection standards, process standards, and alignment standards, were used to assure QA/QC targets to control for experimental variability. Aliquots (200 µl) of 10 mM solutions of isotopically labeled standards were mixed and diluted up to 8000 µl (final concentration 0.25 mM) and aliquoted into a final volume of 20 µl. The aliquots were dried and stored at –80°C until further analysis. To monitor instrument performance, 20 µl of a matrix-free mixture of the internal standards were reconstituted in 100 µl of methanol:water (50:50) and analyzed by multiple reaction monitoring (MRM). Metabolite extraction from the samples was monitored using pooled mouse serum or liver samples and spiked internal standards. The median coefficient of variation (CV) value for the internal standard compounds was 5%. To address overall process variability, metabolomic studies included a set of nine experimental sample technical replicates, which were spaced evenly among the injections for each day. The matrix-free internal standards and serum and liver samples were analyzed twice daily.</p></sec><sec id="s4-16-3"><title>Separation of CoAs and carnitines</title><p>Targeted profiling for CoAs and carnitines in electrospray ionization-positive mode by the RP chromatographic method employed a gradient containing water (solvent A) and acetonitrile (ACN, solvent B, with both solvents containing 0.1% formic acid). Separation of metabolites was performed on a Zorbax Eclipse XDBC18 column (50 × 4.6 mm i.d.; 1.8 μm, Agilent Technologies) maintained at 37°C. The gradient conditions were 0–6 min in 2% B, 6.5 min in 30% B, 7 min in 90% B, 12 min in 95% B; followed by re-equilibration to the initial conditions.</p></sec><sec id="s4-16-4"><title>Separation of glycolysis and TCA metabolites</title><p>Glycolysis and TCA metabolites were separated by normal phase chromatography using solvents containing water (solvent A), solvent A modified by the addition of 5 mM ammonium acetate (pH 9.9), and 100% acetonitrile (solvent B). The binary pump flow rate was 0.2 ml/min with a gradient spanning 80% B to 2% B over 20 min, 2% B to 80% B for 5 min, and 80% B for 13 min. The flow rate was gradually increased during the separation from 0.2 ml/min (0–20 min) to 0.3 ml/min (20–25 min), and then 0.35 ml/min (25–30 min), 0.4 ml/min (30–37.99 min), and finally to 0.2 ml/min (5 min). Metabolites were separated on a Luna Amino (NH2) column (4 µm, 100 A 2.1 × 150 mm, Phenominex) maintained in a temperature-controlled chamber (37°C). All the columns used in this study were washed and reconditioned after every 50 injections.</p></sec><sec id="s4-16-5"><title>Separation of fatty acids</title><p>Targeted profiling for fatty acids employed a reverse phase chromatographic method by a gradient containing water (solvent A) with 10 mM ammonium acetate (pH 8) and 100% methanol (solvent B) on a Luna Phyenyl Hexyl column (3 µm, 2 × 150 mm; Phenominex, CA) maintained at 40°C. The binary pump flow rate was 0.2 ml/min with a gradient spanning 40% B to 50% B over 8 min, 50% B to 67% B over 5 min, hold 67% B for 9 min, 67% B to 100% B over 1 min, hold 100% B for 6 min, 100% B to 40% B over 1 min, and hold 40% B for 7 min.</p></sec><sec id="s4-16-6"><title>Liquid chromatography/mass spectrometry (LC/MS) analyses</title><p>The chromatographic separation of non-lipid metabolites was performed using either reverse phase separation or normal phase online with the unbiased profiling platform based on a 1290 SL Rapid resolution LC and a 6490 triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara, CA). Lipidomics required a Shimadzu CTO-20A Nexera X2 UHPLC coupled with TripleTOF 5600 equipped with a Turbo VTM ion source (AB Sciex, Concord, Canada). Using a dual electrospray ionization source, the samples were independently examined in both positive and negative ionization modes. The data acquisition during the analysis was controlled using the Mass Hunter workstation data acquisition software.</p></sec><sec id="s4-16-7"><title>Lipidomics</title><p>Mouse liver lipids were extracted using a modified Bligh-Dyer method. Briefly, 50 mg of crushed tissue sample from mouse whole liver was used. A 2:2:2 volume ratio of water/methanol/dichloromethane was used for lipid extract at room temperature after spiking internal standards 17:0 LPC, 17:0 PC, 17:0 PE, 17:0 PG, 17:0 ceramide, 17:0 SM, 17:0 PS, 17:0 PA, 17:0 TAG, 17:0 MAG, DAG 16:0/18:1, CE 17:0. The organic layer was collected, followed by a complete drying procedure under nitrogen. Before MS analysis, the dried extract was resuspended in 100 μl of Buffer B (10:5:85 acetonitrile/water/isopropyl alcohol) containing 10 mM NH<sub>4</sub>OAc and subjected to reverse-phase chromatography and LC/MS. Internal standards prepared in chloroform/methanol/water (100 pmol/μl) were LPC 17:0/0:0, PG 17:0/17:0, PE 17:0/17:0, PC 17:0/17:0, TAG 17:0/17:0/17:0, SM 18:1/17:0, MAG 17:0, DAG 16:0/18:1, CE 17:0, ceramide 18:1/17:0, PA 17:0, PI 17:0/20:4, and PS 17:0/17:0.</p><p>For lipid separation, 5 ml of the lipid extract was injected into a 1.8 mm particle 50 × 2.1 mm Acquity HSS UPLC T3 column (Waters). The column heater temperature was set at 55°C. For chromatographic elution, a linear gradient was used over a 20 min total run time, with 60% Solvent A (acetonitrile/water [40:60, v/v] with 10 mM ammonium acetate) and 40% Solvent B (acetonitrile/water/isopropanol [10:5:85 v/v] with 10 mM ammonium acetate) gradient in the first 10 min. The gradient was ramped linearly to 100% Solvent B for 7 min. Then the system was switched back to 60% Solvent B and 40% Solvent A for 3 min. A 0.4 ml/min flow rate was used at an injection volume of 5 μl. The column was equilibrated for 3 min and run at a flow rate of 0.4 ml/min for a total run time of 20 min. TOF MS survey scans (150 ms) and 15 MS/MS scans with a total duty cycle time of 2.4 s were performed. The mass range in both modes was 50–1200 m/z. The acquisition of MS/MS spectra by data-dependent acquisition (DDA) function of the Analyst TF software (AB Sciex).</p><p>The raw data in .mgf format were converted using ProteoWizard software. The NIST MS PepSearch Program was used to search the converted files against LipidBlast libraries. The m/z width was determined via the mass accuracy of internal standards at 0.001 for positive mode and 0.005 for a negative mode at an overall mass error of less than 2 ppm. The minimum match factor at 400 was set for the downstream data processing. The MS/MS identification results from all the files were combined using an in-house software tool to create a library for quantification. The raw data files were searched against this in-house library of known lipids with mass and retention time using Multiquant 1.1.0.26 (ABsciex). The lipid species identified in the positive or negative ion modes were analyzed separately using relative abundance of peak spectra for the downstream analyses. The identified lipids were quantified by normalizing against their respective internal standard.</p></sec><sec id="s4-16-8"><title>Ceramides and lipids</title><p>Lipid extracts are separated on an Acquity UPLC CSH C18 1.7 μm 2.1 × 50 mm column maintained at 60°C connected to an Agilent HiP 1290 Sampler, Agilent 1290 Infinity pump, equipped with an Agilent 1290 Flex Cube and Agilent 6490 triple quadrupole (QQQ) mass spectrometer. In positive ion mode, sphingolipids are detected using dynamic multiple reaction monitoring (dMRM). Source gas temperature is set to 210°C, with an N<sub>2</sub> flow of 11 l/min and a nebulizer pressure of 30 psi. Sheath gas temperature is 400°C, sheath gas (N<sub>2</sub>) flow of 12 l/min, capillary voltage is 4000 V, nozzle voltage 500 V, high-pressure RF 190 V, and low-pressure RF is 120 V. Injection volume is 2 μl, and the samples are analyzed in a randomized order with the pooled QC sample injection eight times throughout the sample queue. Mobile phase A consists of ACN:H<sub>2</sub>O (60:40 v/v) in 10 mM ammonium formate and 0.1% formic acid, and mobile phase B consists of IPA:ACN:H<sub>2</sub>O (90:9:1 v/v) in 10 mM ammonium formate and 0.1% formic acid. The five chromatography gradient starts at 15% mobile phase B, increases to 30% B over 1 min, increases to 60% B from 1 to 2 min, increases to 80% B from 2 to 10 min, and increases to 99% B from 10 to 10.2 min where it is held until 14 min. Post-time is 5 min, and the flow rate is 0.35 ml/min throughout. Collision energies and cell accelerator voltages were optimized using sphingolipid standards with dMRM transitions as [M+H]+→[m/z = 284.3] for dihydroceramides, [M+H]+→[m/z = 287.3] for isotope-labeled dihydroceramides, [M-H<sub>2</sub>O+H]+→[m/z = 264.2] for ceramides, [MH<sub>2</sub>O+H]+→[m/z = 267.2] for isotope-labeled ceramides and [M+H]+→[M-H<sub>2</sub>O+H] for all targets. Sphingolipids and ceramides without available standards are identified based on HR-LC/MS, quasi-molecular ions, and characteristic product ions. Their retention times are either taken from HR-LC/MS data or inferred from the available standards. Results from LC-MS experiments are collected using Agilent Mass Hunter Workstation and analyzed using the software package Agilent Mass Hunter Quant B.07.00. Ceramide and lipid species are quantitated based on peak area ratios to the standards added to the extracts.</p></sec></sec><sec id="s4-17"><title>Analysis of FAD and FMN by IC-HRMS</title><p>To determine the relative abundance of FAD and FMN in mouse liver tissue, extracts were prepared and analyzed by high-resolution mass spectrometry (HRMS). Approximately 20–30 mg of tissue were pulverized in liquid nitrogen then homogenized with a Precellys Tissue Homogenizer. Metabolites were extracted using 80/20 (v/v) methanol/water with 0.1% ammonium hydroxide. Samples were centrifuged at 17,000 × <italic>g</italic> for 5 min at 4°C, supernatants were transferred to clean tubes, followed by evaporation under vacuum. Samples were reconstituted in deionized water, then 10 μl was injected into a Thermo Scientific Dionex ICS-5000+ capillary ion chromatography (IC) system containing a Thermo IonPac AS11 250 × 2 mm 4 μm column. IC flow rate was 360 µl/min (at 30°C), and the gradient conditions are as follows: initial 1 mM KOH, increased to 35 mM at 25 min, increased to 99 mM at 39 min, and held at 99 mM for 10 min. The total run time was 50 min. To increase desolvation for better sensitivity, methanol was delivered by an external pump and combined with the eluent via a low dead volume mixing tee. Data were acquired using a Thermo Orbitrap Fusion Tribrid Mass Spectrometer under ESI negative mode and imported to Thermo Trace Finder software for final analysis. Relative abundance was normalized by tissue weight.</p></sec><sec id="s4-18"><title>Analysis of reduced and oxidized coenzymes by triple quadruple LC-MS</title><p>To determine the relative abundance of ubiquinone (oxidized CoQ10), ubiquinol (reduced CoQ10), ubiquinone-9 (CoQ9), and ubiquinol-9 (reduced CoQ9) in mouse liver samples, extracts were prepared and analyzed by Thermo Scientific TSQ triple quadrupole mass spectrometer coupled with a Dionex UltiMate 3000 HPLC system. Approximately 20–30 mg of tissue were pulverized in liquid nitrogen then homogenized with a Precellys Tissue Homogenizer. Coenzymes were extracted with 500 µl ice-cold 100% isopropanol. Tissue extracts were vortexed, centrifuged at 17,000 × <italic>g</italic> for 5 min at 4°C, and supernatants were transferred to clean autosampler vials. The mobile phase was methanol containing 5 mM ammonium formate. Separations of CoQ9, CoQ10, reduced-CoQ9, and reduced-CoQ10 were achieved on a Kinetex 2.6 µm C18 100 Å, 100 × 4.6 mm column. The flow rate was 400 µl/min at 35°C. The mass spectrometer was operated in the MRM positive ion electrospray mode with the following transitions. CoQ10/oxidized: m/z 863.7→197.1 CoQ10/reduced: m/z 882.7→197.1, CoQ9/oxidized: m/z 795.6 →197.1, and CoQ9/reduced: m/z 814.7 →197.1. Raw data files were imported to Thermo Trace Finder software for final analysis. Relative abundance was normalized by tissue weight.</p></sec><sec id="s4-19"><title>Quantification and statistical analysis</title><p>All measurements were taken from distinct biological samples. Unless otherwise noted, all statistical analyses were performed using GraphPad Prism (version 9) and tests described in the figure legends. In the case of multiple groups, a one- or two-way ANOVA with post-hoc tests were used to determine statistical significance. When only two groups were compared, nonparametric Mann–Whitney tests were used to determine statistical significance. Gene expression and metabolomic heatmaps were plotted as Z-scores using R(4.0.3) and ComplexHeatmap (2.6.2). The species-by-species <italic>t</italic>-test was applied for metabolomics data to identify the top differentially regulated metabolites that passed the nominal threshold p-values. For multiple comparisons, the Sidak procedure was used for false discovery rate (FDR) correction. Statistical analysis of energy balance was performed by ANCOVA with lean body mass as a co-variate (<xref ref-type="bibr" rid="bib35">Mina et al., 2018</xref>). No statistical method was used to predetermine sample size. Unblinded analysis of histology was performed by the investigators. All data are expressed as mean ± SEM, unless otherwise specified.</p></sec><sec id="s4-20"><title>Materials availability</title><p>This study did not generate new unique reagents. The authors declare that reagents utilized are available upon reasonable request to the corresponding author.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Scott Summers is a co-founder and shareholder of Centaurus Therapeutics. There are no competing interests otherwise related to this article</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Software, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con15"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con16"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con17"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN-6411) of the Baylor College of Medicine. Every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Macronutrient compositions of 90% B2D used in the study.</title></caption><media xlink:href="elife-84077-supp1-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Macronutrient compositions of 99% B2D used in the study.</title></caption><media xlink:href="elife-84077-supp2-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Antibodies used in this study.</title></caption><media xlink:href="elife-84077-supp3-v1.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84077-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. RNA-sequencing data have been deposited in GEO under accession code GSE206200. Numerical data used to generate the figures are attached as source data files to each figure. Figure 5 - Source Data 2 and Figure 6 - Source Data 2 contain Western blot scans.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Masschelin</surname><given-names>PM</given-names></name><name><surname>Saha</surname><given-names>PK</given-names></name><name><surname>Ochsner</surname><given-names>SA</given-names></name><name><surname>Cox</surname><given-names>AR</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Felix</surname><given-names>JB</given-names></name><name><surname>Sharp</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Putluri</surname><given-names>V</given-names></name><name><surname>Lorenzi</surname><given-names>PL</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Kaipparettu</surname><given-names>B</given-names></name><name><surname>Putluri</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>Hartig</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Vitamin B2 enables PPARa regulation of fasting glucose availability</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE206200">GSE206200</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was funded by the Nancy Chang, PhD Award for Research Excellence at Baylor College of Medicine, American Diabetes Association #1-18-IBS-105 and NIH R01DK114356 (to SMH). We thank the Gene Vector Core at Baylor College of Medicine for vectors and support. Other BCM core services received support from NCI P30CA125123: Human Tissue Acquisition and Pathology, Metabolomics, and Integrated Microscopy.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alecu</surname><given-names>I</given-names></name><name><surname>Tedeschi</surname><given-names>A</given-names></name><name><surname>Behler</surname><given-names>N</given-names></name><name><surname>Wunderling</surname><given-names>K</given-names></name><name><surname>Lamberz</surname><given-names>C</given-names></name><name><surname>Lauterbach</surname><given-names>MAR</given-names></name><name><surname>Gaebler</surname><given-names>A</given-names></name><name><surname>Ernst</surname><given-names>D</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name><name><surname>Al-Amoudi</surname><given-names>A</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Othman</surname><given-names>A</given-names></name><name><surname>Kuerschner</surname><given-names>L</given-names></name><name><surname>Hornemann</surname><given-names>T</given-names></name><name><surname>Bradke</surname><given-names>F</given-names></name><name><surname>Thiele</surname><given-names>C</given-names></name><name><surname>Penno</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Localization of 1-Deoxysphingolipids to mitochondria induces mitochondrial dysfunction</article-title><source>Journal of Lipid Research</source><volume>58</volume><fpage>42</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1194/jlr.M068676</pub-id><pub-id pub-id-type="pmid">27881717</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Anonymous</collab></person-group><year iso-8601-date="1977">1977</year><article-title>Report of the American Institute of Nurtition ad hoc Committee on Standards for Nutritional Studies</article-title><source>The Journal of Nutrition</source><volume>107</volume><fpage>1340</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1093/jn/107.7.1340</pub-id><pub-id pub-id-type="pmid">874577</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashrafian</surname><given-names>H</given-names></name><name><surname>Czibik</surname><given-names>G</given-names></name><name><surname>Bellahcene</surname><given-names>M</given-names></name><name><surname>Aksentijević</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>AC</given-names></name><name><surname>Mitchell</surname><given-names>SJ</given-names></name><name><surname>Dodd</surname><given-names>MS</given-names></name><name><surname>Kirwan</surname><given-names>J</given-names></name><name><surname>Byrne</surname><given-names>JJ</given-names></name><name><surname>Ludwig</surname><given-names>C</given-names></name><name><surname>Isackson</surname><given-names>H</given-names></name><name><surname>Yavari</surname><given-names>A</given-names></name><name><surname>Støttrup</surname><given-names>NB</given-names></name><name><surname>Contractor</surname><given-names>H</given-names></name><name><surname>Cahill</surname><given-names>TJ</given-names></name><name><surname>Sahgal</surname><given-names>N</given-names></name><name><surname>Ball</surname><given-names>DR</given-names></name><name><surname>Birkler</surname><given-names>RID</given-names></name><name><surname>Hargreaves</surname><given-names>I</given-names></name><name><surname>Tennant</surname><given-names>DA</given-names></name><name><surname>Land</surname><given-names>J</given-names></name><name><surname>Lygate</surname><given-names>CA</given-names></name><name><surname>Johannsen</surname><given-names>M</given-names></name><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Neubauer</surname><given-names>S</given-names></name><name><surname>Redwood</surname><given-names>C</given-names></name><name><surname>de Cabo</surname><given-names>R</given-names></name><name><surname>Ahmet</surname><given-names>I</given-names></name><name><surname>Talan</surname><given-names>M</given-names></name><name><surname>Günther</surname><given-names>UL</given-names></name><name><surname>Robinson</surname><given-names>AJ</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name><name><surname>Pollard</surname><given-names>PJ</given-names></name><name><surname>Tyler</surname><given-names>DJ</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway</article-title><source>Cell Metabolism</source><volume>15</volume><fpage>361</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.01.017</pub-id><pub-id pub-id-type="pmid">22405071</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramaniam</surname><given-names>S</given-names></name><name><surname>Christodoulou</surname><given-names>J</given-names></name><name><surname>Rahman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disorders of riboflavin metabolism</article-title><source>Journal of Inherited Metabolic Disease</source><volume>42</volume><fpage>608</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1002/jimd.12058</pub-id><pub-id pub-id-type="pmid">30680745</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beach</surname><given-names>RS</given-names></name><name><surname>Mantero-Atienza</surname><given-names>E</given-names></name><name><surname>Shor-Posner</surname><given-names>G</given-names></name><name><surname>Javier</surname><given-names>JJ</given-names></name><name><surname>Szapocznik</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Sauberlich</surname><given-names>HE</given-names></name><name><surname>Cornwell</surname><given-names>PE</given-names></name><name><surname>Eisdorfer</surname><given-names>C</given-names></name><name><surname>Baum</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Specific nutrient abnormalities in asymptomatic HIV-1 infection</article-title><source>AIDS</source><volume>6</volume><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1097/00002030-199207000-00013</pub-id><pub-id pub-id-type="pmid">1503689</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bideyan</surname><given-names>L</given-names></name><name><surname>Nagari</surname><given-names>R</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatic transcriptional responses to fasting and feeding</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>635</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1101/gad.348340.121</pub-id><pub-id pub-id-type="pmid">33888557</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bissig-Choisat</surname><given-names>B</given-names></name><name><surname>Alves-Bezerra</surname><given-names>M</given-names></name><name><surname>Zorman</surname><given-names>B</given-names></name><name><surname>Ochsner</surname><given-names>SA</given-names></name><name><surname>Barzi</surname><given-names>M</given-names></name><name><surname>Legras</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Borowiak</surname><given-names>M</given-names></name><name><surname>Dean</surname><given-names>AM</given-names></name><name><surname>York</surname><given-names>RB</given-names></name><name><surname>Galvan</surname><given-names>NTN</given-names></name><name><surname>Goss</surname><given-names>J</given-names></name><name><surname>Lagor</surname><given-names>WR</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name><name><surname>McKenna</surname><given-names>NJ</given-names></name><name><surname>Sumazin</surname><given-names>P</given-names></name><name><surname>Bissig</surname><given-names>K-D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A human liver Chimeric mouse model for non-alcoholic fatty liver disease</article-title><source>JHEP Reports</source><volume>3</volume><elocation-id>100281</elocation-id><pub-id pub-id-type="doi">10.1016/j.jhepr.2021.100281</pub-id><pub-id pub-id-type="pmid">34036256</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bougarne</surname><given-names>N</given-names></name><name><surname>Weyers</surname><given-names>B</given-names></name><name><surname>Desmet</surname><given-names>SJ</given-names></name><name><surname>Deckers</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>DW</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>De Bosscher</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Molecular actions of PPARα in lipid metabolism and inflammation</article-title><source>Endocrine Reviews</source><volume>39</volume><fpage>760</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1210/er.2018-00064</pub-id><pub-id pub-id-type="pmid">30020428</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocker</surname><given-names>CN</given-names></name><name><surname>Yue</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>A</given-names></name><name><surname>Bonzo</surname><given-names>JA</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from Nonparenchymal cells</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>312</volume><fpage>G283</fpage><lpage>G299</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00205.2016</pub-id><pub-id pub-id-type="pmid">28082284</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaurasia</surname><given-names>B</given-names></name><name><surname>Tippetts</surname><given-names>TS</given-names></name><name><surname>Mayoral Monibas</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wilkerson</surname><given-names>JL</given-names></name><name><surname>Sweeney</surname><given-names>CR</given-names></name><name><surname>Pereira</surname><given-names>RF</given-names></name><name><surname>Sumida</surname><given-names>DH</given-names></name><name><surname>Maschek</surname><given-names>JA</given-names></name><name><surname>Cox</surname><given-names>JE</given-names></name><name><surname>Kaddai</surname><given-names>V</given-names></name><name><surname>Lancaster</surname><given-names>GI</given-names></name><name><surname>Siddique</surname><given-names>MM</given-names></name><name><surname>Poss</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>Satapati</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>McLaren</surname><given-names>DG</given-names></name><name><surname>Previs</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Petrov</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Nunes</surname><given-names>CN</given-names></name><name><surname>Howard</surname><given-names>AD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Erion</surname><given-names>MD</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name><name><surname>Holland</surname><given-names>WL</given-names></name><name><surname>Kelley</surname><given-names>DE</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting a Ceramide double bond improves insulin resistance and hepatic steatosis</article-title><source>Science</source><volume>365</volume><fpage>386</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1126/science.aav3722</pub-id><pub-id pub-id-type="pmid">31273070</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>AR</given-names></name><name><surname>Louet</surname><given-names>J-F</given-names></name><name><surname>Saha</surname><given-names>P</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Demayo</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>York</surname><given-names>B</given-names></name><name><surname>Karpen</surname><given-names>S</given-names></name><name><surname>Finegold</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Newgard</surname><given-names>CB</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Absence of the SRC-2 coactivator results in a Glycogenopathy resembling von Gierke’s disease</article-title><source>Science</source><volume>322</volume><fpage>1395</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1126/science.1164847</pub-id><pub-id pub-id-type="pmid">19039140</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname><given-names>DG</given-names></name><name><surname>Ercal</surname><given-names>B</given-names></name><name><surname>d’Avignon</surname><given-names>DA</given-names></name><name><surname>Dietzen</surname><given-names>DJ</given-names></name><name><surname>Crawford</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Impairments of hepatic Gluconeogenesis and Ketogenesis in PPARα-deficient neonatal mice</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>307</volume><fpage>E176</fpage><lpage>E185</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00087.2014</pub-id><pub-id pub-id-type="pmid">24865983</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLany</surname><given-names>JP</given-names></name><name><surname>Horgan</surname><given-names>A</given-names></name><name><surname>Gregor</surname><given-names>A</given-names></name><name><surname>Vockley</surname><given-names>J</given-names></name><name><surname>Harding</surname><given-names>CO</given-names></name><name><surname>Gillingham</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Resting and total energy expenditure of patients with long-chain fatty acid oxidation disorders (LC-Faods)</article-title><source>Molecular Genetics and Metabolism</source><volume>138</volume><elocation-id>107519</elocation-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2023.107519</pub-id><pub-id pub-id-type="pmid">36696737</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>PF</given-names></name><name><surname>Cowgill</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="1947">1947</year><article-title>The nutrition of the Mouse; a difference in the riboflavin requirements of two highly inbred strains</article-title><source>The Journal of Nutrition</source><volume>34</volume><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1093/jn/34.3.273</pub-id><pub-id pub-id-type="pmid">20259193</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouty</surname><given-names>B</given-names></name><name><surname>Frerman</surname><given-names>F</given-names></name><name><surname>Reves</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Riboflavin to treat nucleoside analogue-induced lactic acidosis</article-title><source>Lancet</source><volume>352</volume><fpage>291</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)60266-8</pub-id><pub-id pub-id-type="pmid">9690419</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friederich</surname><given-names>MW</given-names></name><name><surname>Elias</surname><given-names>AF</given-names></name><name><surname>Kuster</surname><given-names>A</given-names></name><name><surname>Laugwitz</surname><given-names>L</given-names></name><name><surname>Larson</surname><given-names>AA</given-names></name><name><surname>Landry</surname><given-names>AP</given-names></name><name><surname>Ellwood-Digel</surname><given-names>L</given-names></name><name><surname>Mirsky</surname><given-names>DM</given-names></name><name><surname>Dimmock</surname><given-names>D</given-names></name><name><surname>Haven</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>MacLean</surname><given-names>KN</given-names></name><name><surname>Styren</surname><given-names>K</given-names></name><name><surname>Schoof</surname><given-names>J</given-names></name><name><surname>Goujon</surname><given-names>L</given-names></name><name><surname>Lefrancois</surname><given-names>T</given-names></name><name><surname>Friederich</surname><given-names>M</given-names></name><name><surname>Coughlin</surname><given-names>CR</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Haack</surname><given-names>TB</given-names></name><name><surname>Van Hove</surname><given-names>JLK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathogenic variants in SQOR Encoding sulfide:Quinone Oxidoreductase are a potentially treatable cause of Leigh disease</article-title><source>Journal of Inherited Metabolic Disease</source><volume>43</volume><fpage>1024</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1002/jimd.12232</pub-id><pub-id pub-id-type="pmid">32160317</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>Z</given-names></name><name><surname>Gui</surname><given-names>T</given-names></name><name><surname>Alecu</surname><given-names>I</given-names></name><name><surname>Lone</surname><given-names>MA</given-names></name><name><surname>Hornemann</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Visentin</surname><given-names>M</given-names></name><name><surname>Hiller</surname><given-names>C</given-names></name><name><surname>Hausler</surname><given-names>S</given-names></name><name><surname>Kullak-Ublick</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Farnesoid X receptor activation induces the degradation of hepatotoxic 1-Deoxysphingolipids in non-alcoholic fatty liver disease</article-title><source>Liver International</source><volume>40</volume><fpage>844</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1111/liv.14340</pub-id><pub-id pub-id-type="pmid">31883408</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves</surname><given-names>MD</given-names></name><name><surname>Hwang</surname><given-names>S-K</given-names></name><name><surname>Pauli</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>CJ</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Hopkins</surname><given-names>BD</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Loughran</surname><given-names>RM</given-names></name><name><surname>Emerling</surname><given-names>BM</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fenofibrate prevents Skeletal muscle loss in mice with lung cancer</article-title><source>PNAS</source><volume>115</volume><fpage>E743</fpage><lpage>E752</lpage><pub-id pub-id-type="doi">10.1073/pnas.1714703115</pub-id><pub-id pub-id-type="pmid">29311302</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammerschmidt</surname><given-names>P</given-names></name><name><surname>Ostkotte</surname><given-names>D</given-names></name><name><surname>Nolte</surname><given-names>H</given-names></name><name><surname>Gerl</surname><given-names>MJ</given-names></name><name><surname>Jais</surname><given-names>A</given-names></name><name><surname>Brunner</surname><given-names>HL</given-names></name><name><surname>Sprenger</surname><given-names>HG</given-names></name><name><surname>Awazawa</surname><given-names>M</given-names></name><name><surname>Nicholls</surname><given-names>HT</given-names></name><name><surname>Turpin-Nolan</surname><given-names>SM</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Krüger</surname><given-names>M</given-names></name><name><surname>Brügger</surname><given-names>B</given-names></name><name><surname>Brüning</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cers6-derived Sphingolipids interact with Mff and promote mitochondrial fragmentation in obesity</article-title><source>Cell</source><volume>177</volume><fpage>1536</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.008</pub-id><pub-id pub-id-type="pmid">31150623</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>HP</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Novoa</surname><given-names>I</given-names></name><name><surname>Lu</surname><given-names>PD</given-names></name><name><surname>Calfon</surname><given-names>M</given-names></name><name><surname>Sadri</surname><given-names>N</given-names></name><name><surname>Yun</surname><given-names>C</given-names></name><name><surname>Popko</surname><given-names>B</given-names></name><name><surname>Paules</surname><given-names>R</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Hettmann</surname><given-names>T</given-names></name><name><surname>Leiden</surname><given-names>JM</given-names></name><name><surname>Ron</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An integrated stress response regulates amino acid metabolism and resistance to oxidative stress</article-title><source>Molecular Cell</source><volume>11</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(03)00105-9</pub-id><pub-id pub-id-type="pmid">12667446</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houten</surname><given-names>SM</given-names></name><name><surname>Violante</surname><given-names>S</given-names></name><name><surname>Ventura</surname><given-names>FV</given-names></name><name><surname>Wanders</surname><given-names>RJA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Biochemistry and physiology of mitochondrial fatty acid Β-oxidation and its genetic disorders</article-title><source>Annual Review of Physiology</source><volume>78</volume><fpage>23</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105045</pub-id><pub-id pub-id-type="pmid">26474213</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Saha</surname><given-names>PK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Hussain</surname><given-names>MM</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Molecular characterization of the role of orphan receptor small Heterodimer partner in development of fatty liver</article-title><source>Hepatology</source><volume>46</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1002/hep.21632</pub-id><pub-id pub-id-type="pmid">17526026</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>E</given-names></name><name><surname>Farrell</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Robertson</surname><given-names>G</given-names></name><name><surname>Leclercq</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Administration of the potent Pparalpha agonist, Wy-14,643, reverses nutritional fibrosis and Steatohepatitis in mice</article-title><source>Hepatology</source><volume>39</volume><fpage>1286</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1002/hep.20170</pub-id><pub-id pub-id-type="pmid">15122757</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackevicius</surname><given-names>CA</given-names></name><name><surname>Tu</surname><given-names>JV</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>Carreon</surname><given-names>D</given-names></name><name><surname>Krumholz</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Use of fibrates in the United States and Canada</article-title><source>JAMA</source><volume>305</volume><fpage>1217</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.353</pub-id><pub-id pub-id-type="pmid">21427374</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>SE</given-names></name><name><surname>Heaton</surname><given-names>N</given-names></name><name><surname>Potter</surname><given-names>D</given-names></name><name><surname>Pernet</surname><given-names>A</given-names></name><name><surname>Umpleby</surname><given-names>MA</given-names></name><name><surname>Amiel</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Renal glucose production compensates for the liver during the Anhepatic phase of liver transplantation</article-title><source>Diabetes</source><volume>49</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.2337/diabetes.49.3.450</pub-id><pub-id pub-id-type="pmid">10868968</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabat</surname><given-names>GC</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Rohan</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dietary intake of selected B vitamins in relation to risk of major cancers in women</article-title><source>British Journal of Cancer</source><volume>99</volume><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604540</pub-id><pub-id pub-id-type="pmid">18665162</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Seydoux</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Peroxisome Proliferator-activated receptor alpha mediates the adaptive response to fasting</article-title><source>The Journal of Clinical Investigation</source><volume>103</volume><fpage>1489</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1172/JCI6223</pub-id><pub-id pub-id-type="pmid">10359558</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>S</given-names></name><name><surname>Mandard</surname><given-names>S</given-names></name><name><surname>Escher</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Tafuri</surname><given-names>S</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The peroxisome Proliferator-activated receptor alpha regulates amino acid metabolism</article-title><source>FASEB Journal</source><volume>15</volume><fpage>1971</fpage><lpage>1978</lpage><pub-id pub-id-type="doi">10.1096/fj.01-0147com</pub-id><pub-id pub-id-type="pmid">11532977</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettner</surname><given-names>NM</given-names></name><name><surname>Voicu</surname><given-names>H</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Coarfa</surname><given-names>C</given-names></name><name><surname>Sreekumar</surname><given-names>A</given-names></name><name><surname>Putluri</surname><given-names>N</given-names></name><name><surname>Katchy</surname><given-names>CA</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Circadian homeostasis of liver metabolism suppresses Hepatocarcinogenesis</article-title><source>Cancer Cell</source><volume>30</volume><fpage>909</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.007</pub-id><pub-id pub-id-type="pmid">27889186</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Choi</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Wooton-Kee</surname><given-names>CR</given-names></name><name><surname>Arizpe</surname><given-names>A</given-names></name><name><surname>Anakk</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Hartig</surname><given-names>SM</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Constitutive Androstane receptor differentially regulates bile acid homeostasis in Mouse models of Intrahepatic cholestasis</article-title><source>Hepatology Communications</source><volume>3</volume><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1002/hep4.1274</pub-id><pub-id pub-id-type="pmid">30620001</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>E-H</given-names></name><name><surname>Chernis</surname><given-names>N</given-names></name><name><surname>Saha</surname><given-names>PK</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Bader</surname><given-names>DA</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Rajapakshe</surname><given-names>K</given-names></name><name><surname>Hamilton</surname><given-names>MP</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Perera</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>York</surname><given-names>B</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name><name><surname>Coarfa</surname><given-names>C</given-names></name><name><surname>Bajaj</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><name><surname>Deng</surname><given-names>T</given-names></name><name><surname>McGuire</surname><given-names>SE</given-names></name><name><surname>Hartig</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>miR-30A Remodels subcutaneous Adipose tissue inflammation to improve insulin sensitivity in obesity</article-title><source>Diabetes</source><volume>67</volume><fpage>2541</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.2337/db17-1378</pub-id><pub-id pub-id-type="pmid">30002134</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Pineau</surname><given-names>T</given-names></name><name><surname>Drago</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Owens</surname><given-names>JW</given-names></name><name><surname>Kroetz</surname><given-names>DL</given-names></name><name><surname>Fernandez-Salguero</surname><given-names>PM</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Targeted disruption of the alpha Isoform of the peroxisome Proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators</article-title><source>Molecular and Cellular Biology</source><volume>15</volume><fpage>3012</fpage><lpage>3022</lpage><pub-id pub-id-type="doi">10.1128/MCB.15.6.3012</pub-id><pub-id pub-id-type="pmid">7539101</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nutrient-sensing nuclear receptors coordinate Autophagy</article-title><source>Nature</source><volume>516</volume><fpage>112</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/nature13961</pub-id><pub-id pub-id-type="pmid">25383539</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luukkonen</surname><given-names>PK</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Sädevirta</surname><given-names>S</given-names></name><name><surname>Leivonen</surname><given-names>M</given-names></name><name><surname>Arola</surname><given-names>J</given-names></name><name><surname>Orešič</surname><given-names>M</given-names></name><name><surname>Hyötyläinen</surname><given-names>T</given-names></name><name><surname>Yki-Järvinen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatic Ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease</article-title><source>Journal of Hepatology</source><volume>64</volume><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.01.002</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mina</surname><given-names>AI</given-names></name><name><surname>LeClair</surname><given-names>RA</given-names></name><name><surname>LeClair</surname><given-names>KB</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name><name><surname>Lantier</surname><given-names>L</given-names></name><name><surname>Banks</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Calr: A web-based analysis tool for indirect Calorimetry experiments</article-title><source>Cell Metabolism</source><volume>28</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.06.019</pub-id><pub-id pub-id-type="pmid">30017358</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagner</surname><given-names>A</given-names></name><name><surname>Polizzi</surname><given-names>A</given-names></name><name><surname>Fouché</surname><given-names>E</given-names></name><name><surname>Ducheix</surname><given-names>S</given-names></name><name><surname>Lippi</surname><given-names>Y</given-names></name><name><surname>Lasserre</surname><given-names>F</given-names></name><name><surname>Barquissau</surname><given-names>V</given-names></name><name><surname>Régnier</surname><given-names>M</given-names></name><name><surname>Lukowicz</surname><given-names>C</given-names></name><name><surname>Benhamed</surname><given-names>F</given-names></name><name><surname>Iroz</surname><given-names>A</given-names></name><name><surname>Bertrand-Michel</surname><given-names>J</given-names></name><name><surname>Al Saati</surname><given-names>T</given-names></name><name><surname>Cano</surname><given-names>P</given-names></name><name><surname>Mselli-Lakhal</surname><given-names>L</given-names></name><name><surname>Mithieux</surname><given-names>G</given-names></name><name><surname>Rajas</surname><given-names>F</given-names></name><name><surname>Lagarrigue</surname><given-names>S</given-names></name><name><surname>Pineau</surname><given-names>T</given-names></name><name><surname>Loiseau</surname><given-names>N</given-names></name><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Langin</surname><given-names>D</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name><name><surname>Guillou</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD</article-title><source>Gut</source><volume>65</volume><fpage>1202</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310798</pub-id><pub-id pub-id-type="pmid">26838599</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthusamy</surname><given-names>T</given-names></name><name><surname>Cordes</surname><given-names>T</given-names></name><name><surname>Handzlik</surname><given-names>MK</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>EW</given-names></name><name><surname>Gengatharan</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>AFM</given-names></name><name><surname>Badur</surname><given-names>MG</given-names></name><name><surname>Kolar</surname><given-names>MJ</given-names></name><name><surname>Wallace</surname><given-names>M</given-names></name><name><surname>Saghatelian</surname><given-names>A</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Serine restriction alters Sphingolipid diversity to constrain tumour growth</article-title><source>Nature</source><volume>586</volume><fpage>790</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2609-x</pub-id><pub-id pub-id-type="pmid">32788725</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niopek</surname><given-names>K</given-names></name><name><surname>Üstünel</surname><given-names>BE</given-names></name><name><surname>Seitz</surname><given-names>S</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><name><surname>Zota</surname><given-names>A</given-names></name><name><surname>Mattijssen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sijmonsma</surname><given-names>T</given-names></name><name><surname>Feuchter</surname><given-names>Y</given-names></name><name><surname>Gail</surname><given-names>AM</given-names></name><name><surname>Leuchs</surname><given-names>B</given-names></name><name><surname>Niopek</surname><given-names>D</given-names></name><name><surname>Staufer</surname><given-names>O</given-names></name><name><surname>Brune</surname><given-names>M</given-names></name><name><surname>Sticht</surname><given-names>C</given-names></name><name><surname>Gretz</surname><given-names>N</given-names></name><name><surname>Müller-Decker</surname><given-names>K</given-names></name><name><surname>Hammes</surname><given-names>H-P</given-names></name><name><surname>Nawroth</surname><given-names>P</given-names></name><name><surname>Fleming</surname><given-names>T</given-names></name><name><surname>Conkright</surname><given-names>MD</given-names></name><name><surname>Blüher</surname><given-names>M</given-names></name><name><surname>Zeigerer</surname><given-names>A</given-names></name><name><surname>Herzig</surname><given-names>S</given-names></name><name><surname>Berriel Diaz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A hepatic Gabp-AMPK axis links inflammatory signaling to systemic vascular damage</article-title><source>Cell Reports</source><volume>20</volume><fpage>1422</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.023</pub-id><pub-id pub-id-type="pmid">28793265</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochsner</surname><given-names>SA</given-names></name><name><surname>Abraham</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>McOwiti</surname><given-names>A</given-names></name><name><surname>Kankanamge</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Andreano</surname><given-names>K</given-names></name><name><surname>Hamilton</surname><given-names>RA</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Gantner</surname><given-names>ML</given-names></name><name><surname>Dehart</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>S</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Becnel</surname><given-names>LB</given-names></name><name><surname>Bridges</surname><given-names>D</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Huss</surname><given-names>JM</given-names></name><name><surname>Stossi</surname><given-names>F</given-names></name><name><surname>Foulds</surname><given-names>CE</given-names></name><name><surname>Kralli</surname><given-names>A</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name><name><surname>McKenna</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The signaling pathways project, an integrated 'Omics Knowledgebase for mammalian cellular signaling pathways</article-title><source>Scientific Data</source><volume>6</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.1038/s41597-019-0193-4</pub-id><pub-id pub-id-type="pmid">31672983</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshida</surname><given-names>K</given-names></name><name><surname>Vasani</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>RS</given-names></name><name><surname>Applegate</surname><given-names>D</given-names></name><name><surname>Rosen</surname><given-names>M</given-names></name><name><surname>Abbott</surname><given-names>B</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Aleksunes</surname><given-names>LM</given-names></name><name><surname>Klaassen</surname><given-names>C</given-names></name><name><surname>Corton</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification of Modulators of the nuclear receptor peroxisome Proliferator-activated receptor Α (PPARα) in a mouse liver gene expression compendium</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0112655</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112655</pub-id><pub-id pub-id-type="pmid">25689681</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>de Lima Morais</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Barrette</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>C</given-names></name><name><surname>Jacques</surname><given-names>P-É</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metaboanalyst 5.0: Narrowing the gap between raw spectra and functional insights</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>W388</fpage><lpage>W396</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab382</pub-id><pub-id pub-id-type="pmid">34019663</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Kaddai</surname><given-names>V</given-names></name><name><surname>Ching</surname><given-names>J</given-names></name><name><surname>Fridianto</surname><given-names>KT</given-names></name><name><surname>Sieli</surname><given-names>RJ</given-names></name><name><surname>Sugii</surname><given-names>S</given-names></name><name><surname>Summers</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A role for Ceramides, but not Sphingomyelins, as antagonists of insulin signaling and mitochondrial metabolism in C2C12 Myotubes</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>23978</fpage><lpage>23988</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.737684</pub-id><pub-id pub-id-type="pmid">27703011</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>VR</given-names></name><name><surname>Eckel-Mahan</surname><given-names>K</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name><name><surname>Baldi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Circadiomics: integrating circadian genomics, transcriptomics, proteomics and metabolomics</article-title><source>Nature Methods</source><volume>9</volume><fpage>772</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2111</pub-id><pub-id pub-id-type="pmid">22847108</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Riboflavin (vitamin B-2) and health</article-title><source>The American Journal of Clinical Nutrition</source><volume>77</volume><fpage>1352</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1093/ajcn/77.6.1352</pub-id><pub-id pub-id-type="pmid">12791609</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and Cervical cancer</article-title><source>The Journal of Nutrition</source><volume>135</volume><fpage>2960S</fpage><lpage>2966S</lpage><pub-id pub-id-type="doi">10.1093/jn/135.12.2960S</pub-id><pub-id pub-id-type="pmid">16317155</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>P</given-names></name><name><surname>Mirshahi</surname><given-names>F</given-names></name><name><surname>Cheung</surname><given-names>O</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Maher</surname><given-names>JW</given-names></name><name><surname>Kellum</surname><given-names>JM</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Activation and dysregulation of the unfolded protein response in Nonalcoholic fatty liver disease</article-title><source>Gastroenterology</source><volume>134</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.10.039</pub-id><pub-id pub-id-type="pmid">18082745</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinaldo</surname><given-names>P</given-names></name><name><surname>Matern</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Fatty acid oxidation disorders</article-title><source>Annual Review of Physiology</source><volume>64</volume><fpage>477</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.64.082201.154705</pub-id><pub-id pub-id-type="pmid">11826276</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivlin</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Riboflavin metabolism</article-title><source>The New England Journal of Medicine</source><volume>283</volume><fpage>463</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1056/NEJM197008272830906</pub-id><pub-id pub-id-type="pmid">4915004</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Lactic Acidemia and mitochondrial disease</article-title><source>Molecular Genetics and Metabolism</source><volume>89</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2006.05.015</pub-id><pub-id pub-id-type="pmid">16854608</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>JT</given-names></name><name><surname>Lerin</surname><given-names>C</given-names></name><name><surname>Haas</surname><given-names>W</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Nutrient control of glucose homeostasis through a complex of PGC-1Alpha and Sirt1</article-title><source>Nature</source><volume>434</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nature03354</pub-id><pub-id pub-id-type="pmid">15744310</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolfe</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cellular energy utilization and molecular origin of Standard metabolic rate in mammals</article-title><source>Physiological Reviews</source><volume>77</volume><fpage>731</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1152/physrev.1997.77.3.731</pub-id><pub-id pub-id-type="pmid">9234964</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>PK</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Martinez-Botas</surname><given-names>J</given-names></name><name><surname>Sunehag</surname><given-names>AL</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Metabolic adaptations in the absence of Perilipin: Increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in Perilipin-null mice</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>35150</fpage><lpage>35158</lpage><pub-id pub-id-type="doi">10.1074/jbc.M405499200</pub-id><pub-id pub-id-type="pmid">15197189</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satapati</surname><given-names>S</given-names></name><name><surname>Kucejova</surname><given-names>B</given-names></name><name><surname>Duarte</surname><given-names>JAG</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Reynolds</surname><given-names>L</given-names></name><name><surname>Sunny</surname><given-names>NE</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Nair</surname><given-names>LA</given-names></name><name><surname>Livingston</surname><given-names>KA</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Merritt</surname><given-names>ME</given-names></name><name><surname>Sherry</surname><given-names>AD</given-names></name><name><surname>Malloy</surname><given-names>CR</given-names></name><name><surname>Shelton</surname><given-names>JM</given-names></name><name><surname>Lambert</surname><given-names>J</given-names></name><name><surname>Parks</surname><given-names>EJ</given-names></name><name><surname>Corbin</surname><given-names>I</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Browning</surname><given-names>JD</given-names></name><name><surname>Burgess</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>4447</fpage><lpage>4462</lpage><pub-id pub-id-type="doi">10.1172/JCI82204</pub-id><pub-id pub-id-type="pmid">26571396</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholtes</surname><given-names>C</given-names></name><name><surname>Giguère</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Transcriptional control of energy metabolism by nuclear receptors</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>23</volume><fpage>750</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00486-7</pub-id><pub-id pub-id-type="pmid">35577989</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciacovelli</surname><given-names>M</given-names></name><name><surname>Gonçalves</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>TI</given-names></name><name><surname>Zecchini</surname><given-names>VR</given-names></name><name><surname>da Costa</surname><given-names>ASH</given-names></name><name><surname>Gaude</surname><given-names>E</given-names></name><name><surname>Drubbel</surname><given-names>AV</given-names></name><name><surname>Theobald</surname><given-names>SJ</given-names></name><name><surname>Abbo</surname><given-names>SR</given-names></name><name><surname>Tran</surname><given-names>MGB</given-names></name><name><surname>Rajeeve</surname><given-names>V</given-names></name><name><surname>Cardaci</surname><given-names>S</given-names></name><name><surname>Foster</surname><given-names>S</given-names></name><name><surname>Yun</surname><given-names>H</given-names></name><name><surname>Cutillas</surname><given-names>P</given-names></name><name><surname>Warren</surname><given-names>A</given-names></name><name><surname>Gnanapragasam</surname><given-names>V</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Franze</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>B</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fumarate is an epigenetic modifier that elicits epithelial-to-Mesenchymal transition</article-title><source>Nature</source><volume>540</volume><fpage>544</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nature20144</pub-id><pub-id pub-id-type="pmid">27760119</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seminotti</surname><given-names>B</given-names></name><name><surname>Grings</surname><given-names>M</given-names></name><name><surname>Glänzel</surname><given-names>NM</given-names></name><name><surname>Vockley</surname><given-names>J</given-names></name><name><surname>Leipnitz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Peroxisome Proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders</article-title><source>Biochemical Pharmacology</source><volume>209</volume><elocation-id>115433</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2023.115433</pub-id><pub-id pub-id-type="pmid">36709926</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Fortuno</surname><given-names>ES</given-names><suffix>III</suffix></name><name><surname>Suh</surname><given-names>JM</given-names></name><name><surname>Stenesen</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Parks</surname><given-names>EJ</given-names></name><name><surname>Adams</surname><given-names>CM</given-names></name><name><surname>Townes</surname><given-names>T</given-names></name><name><surname>Graff</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Atf4 regulates obesity, glucose homeostasis, and energy expenditure</article-title><source>Diabetes</source><volume>58</volume><fpage>2565</fpage><lpage>2573</lpage><pub-id pub-id-type="doi">10.2337/db09-0335</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Gerlach</surname><given-names>BD</given-names></name><name><surname>Yurdagul</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Moore</surname><given-names>MP</given-names></name><name><surname>Zeldin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cd47-SIRPα axis blockade in NASH promotes Necroptotic hepatocyte clearance by liver Macrophages and decreases hepatic fibrosis</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabp8309</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abp8309</pub-id><pub-id pub-id-type="pmid">36417485</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimano</surname><given-names>H</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Isoform 1C of Sterol regulatory element binding protein is less active than Isoform 1A in livers of transgenic mice and in cultured cells</article-title><source>The Journal of Clinical Investigation</source><volume>99</volume><fpage>846</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1172/JCI119248</pub-id><pub-id pub-id-type="pmid">9062341</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="software"><person-group person-group-type="author"><collab>signaling-pathways-project</collab></person-group><year iso-8601-date="2023">2023</year><data-title>SPP Ominer U</data-title><version designator="swh:1:rev:d95703fb6c298f3ed68e96bf8f35aa02f730dbb7">swh:1:rev:d95703fb6c298f3ed68e96bf8f35aa02f730dbb7</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:ebd95da05256d8018a9de142173139d5735d0cfe;origin=https://github.com/signaling-pathways-project/ominer;visit=swh:1:snp:571442c51983078fdc617a12b4b88f36944acbab;anchor=swh:1:rev:d95703fb6c298f3ed68e96bf8f35aa02f730dbb7">https://archive.softwareheritage.org/swh:1:dir:ebd95da05256d8018a9de142173139d5735d0cfe;origin=https://github.com/signaling-pathways-project/ominer;visit=swh:1:snp:571442c51983078fdc617a12b4b88f36944acbab;anchor=swh:1:rev:d95703fb6c298f3ed68e96bf8f35aa02f730dbb7</ext-link></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinal</surname><given-names>CJ</given-names></name><name><surname>Tohkin</surname><given-names>M</given-names></name><name><surname>Miyata</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Lambert</surname><given-names>G</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis</article-title><source>Cell</source><volume>102</volume><fpage>731</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)00062-3</pub-id><pub-id pub-id-type="pmid">11030617</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stec</surname><given-names>DE</given-names></name><name><surname>Gordon</surname><given-names>DM</given-names></name><name><surname>Hipp</surname><given-names>JA</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>ZL</given-names></name><name><surname>Franco</surname><given-names>NR</given-names></name><name><surname>Robison</surname><given-names>JW</given-names></name><name><surname>Anderson</surname><given-names>CD</given-names></name><name><surname>Stec</surname><given-names>DF</given-names></name><name><surname>Hinds</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity</article-title><source>American Journal of Physiology. Regulatory, Integrative and Comparative Physiology</source><volume>317</volume><fpage>R733</fpage><lpage>R745</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00153.2019</pub-id><pub-id pub-id-type="pmid">31483154</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>H</given-names></name><name><surname>Gomez-Duran</surname><given-names>A</given-names></name><name><surname>Pyle</surname><given-names>A</given-names></name><name><surname>Hopton</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>J</given-names></name><name><surname>Stefanetti</surname><given-names>RJ</given-names></name><name><surname>Charman</surname><given-names>SJ</given-names></name><name><surname>Parikh</surname><given-names>JD</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Viscomi</surname><given-names>C</given-names></name><name><surname>Jakovljevic</surname><given-names>DG</given-names></name><name><surname>Hollingsworth</surname><given-names>KG</given-names></name><name><surname>Robinson</surname><given-names>AJ</given-names></name><name><surname>Taylor</surname><given-names>RW</given-names></name><name><surname>Bottolo</surname><given-names>L</given-names></name><name><surname>Horvath</surname><given-names>R</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metabolic effects of Bezafibrate in mitochondrial disease</article-title><source>EMBO Molecular Medicine</source><volume>12</volume><elocation-id>e11589</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.201911589</pub-id><pub-id pub-id-type="pmid">32107855</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treberg</surname><given-names>JR</given-names></name><name><surname>Quinlan</surname><given-names>CL</given-names></name><name><surname>Brand</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Evidence for two sites of superoxide production by mitochondrial NADH-Ubiquinone Oxidoreductase (complex I)</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>27103</fpage><lpage>27110</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.252502</pub-id><pub-id pub-id-type="pmid">21659507</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzoulaki</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>CJ</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>Q</given-names></name><name><surname>Brown</surname><given-names>IJ</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Van Horn</surname><given-names>L</given-names></name><name><surname>Daviglus</surname><given-names>ML</given-names></name><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A nutrient-wide Association study on blood pressure</article-title><source>Circulation</source><volume>126</volume><fpage>2456</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.114058</pub-id><pub-id pub-id-type="pmid">23093587</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zutphen</surname><given-names>T</given-names></name><name><surname>Ciapaite</surname><given-names>J</given-names></name><name><surname>Bloks</surname><given-names>VW</given-names></name><name><surname>Ackereley</surname><given-names>C</given-names></name><name><surname>Gerding</surname><given-names>A</given-names></name><name><surname>Jurdzinski</surname><given-names>A</given-names></name><name><surname>de Moraes</surname><given-names>RA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wolters</surname><given-names>JC</given-names></name><name><surname>Bischoff</surname><given-names>R</given-names></name><name><surname>Wanders</surname><given-names>RJ</given-names></name><name><surname>Houten</surname><given-names>SM</given-names></name><name><surname>Bronte-Tinkew</surname><given-names>D</given-names></name><name><surname>Shatseva</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name><name><surname>Reijngoud</surname><given-names>D-J</given-names></name><name><surname>Bakker</surname><given-names>BM</given-names></name><name><surname>Jonker</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>PK</given-names></name><name><surname>Bandsma</surname><given-names>RHJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Malnutrition-associated liver steatosis and ATP depletion is caused by Peroxisomal and mitochondrial dysfunction</article-title><source>Journal of Hepatology</source><volume>65</volume><fpage>1198</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2016.05.046</pub-id><pub-id pub-id-type="pmid">27312946</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vockley</surname><given-names>J</given-names></name><name><surname>Ensenauer</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Isovaleric Acidemia: New aspects of genetic and Phenotypic heterogeneity</article-title><source>American Journal of Medical Genetics. Part C, Seminars in Medical Genetics</source><volume>142C</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/ajmg.c.30089</pub-id><pub-id pub-id-type="pmid">16602101</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>JS</given-names></name><name><surname>Steele</surname><given-names>R</given-names></name><name><surname>De bodo</surname><given-names>RC</given-names></name><name><surname>Altszuler</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>Effect of insulin on utilization and production of circulating glucose</article-title><source>The American Journal of Physiology</source><volume>189</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1152/ajplegacy.1957.189.1.43</pub-id><pub-id pub-id-type="pmid">13424687</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Coller</surname><given-names>HA</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Hedvat</surname><given-names>CV</given-names></name><name><surname>Perl</surname><given-names>AE</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Sharp</surname><given-names>KA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The common feature of leukemia-associated Idh1 and Idh2 mutations is a Neomorphic enzyme activity converting alpha-Ketoglutarate to 2-Hydroxyglutarate</article-title><source>Cancer Cell</source><volume>17</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.020</pub-id><pub-id pub-id-type="pmid">20171147</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waskowicz</surname><given-names>LR</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Landau</surname><given-names>DJ</given-names></name><name><surname>Brooks</surname><given-names>ED</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Yavarow</surname><given-names>ZA</given-names></name><name><surname>Kudo</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>SP</given-names></name><name><surname>Huat</surname><given-names>BB</given-names></name><name><surname>Yen</surname><given-names>PM</given-names></name><name><surname>Koeberl</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bezafibrate induces Autophagy and improves hepatic lipid metabolism in Glycogen storage disease type IA</article-title><source>Human Molecular Genetics</source><volume>28</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy343</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>K</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Pok</surname><given-names>JY</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ETFDH mutations and Flavin Adenine Dinucleotide homeostasis disturbance are essential for developing riboflavin-responsive multiple Acyl-coenzyme a Dehydrogenation deficiency</article-title><source>Annals of Neurology</source><volume>84</volume><fpage>659</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1002/ana.25338</pub-id><pub-id pub-id-type="pmid">30232818</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Stroup</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Bawa</surname><given-names>FC</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Gopoju</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatocyte nuclear factor 4Α prevents the steatosis-to-NASH progression by regulating P53 and bile acid signaling (in mice)</article-title><source>Hepatology</source><volume>73</volume><fpage>2251</fpage><lpage>2265</lpage><pub-id pub-id-type="doi">10.1002/hep.31604</pub-id><pub-id pub-id-type="pmid">33098092</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CS</given-names></name><name><surname>McCormick</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>Degradation and excretion of riboflavin in the rat</article-title><source>The Journal of Nutrition</source><volume>93</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1093/jn/93.4.445</pub-id><pub-id pub-id-type="pmid">6082656</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Garcia Canaveras</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Jang</surname><given-names>C</given-names></name><name><surname>Mayr</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ghergurovich</surname><given-names>JM</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Morscher</surname><given-names>RJ</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Serine catabolism feeds NADH when respiration is impaired</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>809</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.02.017</pub-id><pub-id pub-id-type="pmid">32187526</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavarow</surname><given-names>ZA</given-names></name><name><surname>Kang</surname><given-names>H-R</given-names></name><name><surname>Waskowicz</surname><given-names>LR</given-names></name><name><surname>Bay</surname><given-names>B-H</given-names></name><name><surname>Young</surname><given-names>SP</given-names></name><name><surname>Yen</surname><given-names>PM</given-names></name><name><surname>Koeberl</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fenofibrate rapidly decreases hepatic lipid and Glycogen storage in neonatal mice with Glycogen storage disease type IA</article-title><source>Human Molecular Genetics</source><volume>29</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz290</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pyruvate kinase M2 promotes de novo Serine synthesis to sustain Mtorc1 activity and cell proliferation</article-title><source>PNAS</source><volume>109</volume><fpage>6904</fpage><lpage>6909</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204176109</pub-id><pub-id pub-id-type="pmid">22509023</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84077.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tontonoz</surname><given-names>Peter</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.16.512439" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.16.512439"/></front-stub><body><p>This paper provides important findings on the metabolic roles of vitamin B2 in the liver that will be of broad interest. Convincing data establish the effects of vitamin B2 deficiency on body composition, energy expenditure, and glucose metabolism.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84077.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tontonoz</surname><given-names>Peter</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>University of California, Los Angeles</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.16.512439">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.10.16.512439v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Vitamin B2 enables peroxisome proliferator-activated receptor a regulation of fasting glucose availability&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by David James as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1: The authors state that riboflavin deficiency alters body composition and energy expenditure and that they were surprised the stunted body weight phenotype of B2D did not arise from higher energy expenditure. However, energy expenditure (EE) was not actually calculated to support these two statements. RER should be calculated to reflect glucose homeostasis and metabolic flexibility.</p><p>2: The B2D mice likely display lower energy expenditure (estimated from lower O2 consumption), lower activity, and similar food intake, but are leaner. The question is why? What is then the role of FAD for energy balance? Importantly, does B2D induce lipodystrophy in a manner similar to IEMs?</p><p>3: I highly recommend the authors subject the mice to metabolic cages during the first 2 weeks of the diet when body weights are still identical between groups, rather than after 4 weeks of the diet. According to PMID:22205519, once obesity or leanness has developed, behavioral and metabolic alterations triggered by the body weight change may obscure or confound the processes that caused the changes in body weight and/or body composition in the first place. Thus, assessing body weight and body composition phenotypes requires a careful analysis of the various factors that might affect these phenotypes. If changes in caloric intake or energy expenditure are observed before the change in body weight or fat mass, it is more likely that one can attribute the difference to these changes.</p><p>5. As mammals cannot synthesize vitamin B2 and diet remains the only available source of FAD, why reducing vitamin B2 in the diet by 90% does not impact liver FAD levels nor influence energy balance (Figure S1)? How do the mice adapt to a 90% reduction in vitamin B2 intake? Is a 90% reduction enough to monitor the complete metabolic phenotype of vitamin B12 deficiency?</p><p>6. The authors state that FAD is required for hepatic glucose production during fasting. However, the data presented in Figure 2a show that liver FAD displays the opposite 24-h rhythm to liver glucose. It is not ideal to show hepatic glucose level, as the liver secrete glucose into the circulation. The authors should instead plot the 24-h rhythm of fed/fasted liver FAD levels and the corresponding fed/fasted blood glucose levels. According to previous publications, liver FAD levels usually coincide with blood glucose.</p><p>7. Authors normalized relative abundances/fold changes from metabolomics measurements to tissue weight. Normalization to the total protein level would be more suitable.</p><p>8. In Figure 4b, it is surprising to observe that the body weights of the mice are significantly different at week 0 before any diet interventions. The authors should provide an explanation for this data. This is in fact different from the data presented in Figure 1d (data shown in % for some reason). Another question is why this experiment used 9 weeks of diet while other experiments used 4 weeks of diet. Figure 1d, and Figure 3d showed % weight change during the 4 weeks of diet, and absolute body weights should also be shown during the 4 weeks as shown in Figure 4b. Consistency in presenting the data would help in comparing the results of different experiments.</p><p>9. Figure 5d shows a representative protein blotted for each complex (Total OXPHOS Rodent WB Antibody Cocktail, ab110413), which unfortunately does not represent the whole complex. Thus, the authors cannot conclude that B2D and fenofibrate lacked meaningful impacts on relative levels of oxidative phosphorylation proteins. It would be surprising that, if PPARa activity is impacted, some genes encoding various subunits of these complexes would not change as many are known as direct targets of PPARa.</p><p>10. For the heatmaps shown in Figure 6a, 6d, the authors compared Ctrl vs B2D, and Ctrl FF vs B2D FF individually, with no comparison between -FF and +FF groups because they are not comparable considering the different lengths of diet (4 weeks vs. 9 weeks) and no placebo gavage for the -FF group. Nonetheless, the authors compared 4 groups together in Figure 5a, 5b, 5c, 5d, 5e, and 6e. Are they different samples? If not, this analysis is flawed.</p><p>11. In Figure 2b, the authors perform an &quot;HGP&quot; (hepatic glucose production). However, in the methods, they state that they inject radioactive glucose, and then measure plasma glucose. This experiment would test glucose consumption and not production. Next to this panel, there is a pyruvate tolerance test which is the correct experiment. Is (a) the HGP experimental methods a typo and they actually used radioactive pyruvate? Or did they (b) actually measure glucose consumption by injecting radioactive glucose? If (a), please correct this typo. If (b), test glucose production by injecting radioactive pyruvate rather than radioactive glucose if possible.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84077.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1: The authors state that riboflavin deficiency alters body composition and energy expenditure and that they were surprised the stunted body weight phenotype of B2D did not arise from higher energy expenditure. However, energy expenditure (EE) was not actually calculated to support these two statements. RER should be calculated to reflect glucose homeostasis and metabolic flexibility.</p></disp-quote><p>Thank you for the suggestion. We included measurements of energy expenditure and RER in the revised manuscript, which support our conclusion that increased energy expenditure does not account for the weight differences between B2D and control. Please see revised Figures 1, 3, and Supplemental Figures 1 and 2.</p><disp-quote content-type="editor-comment"><p>2: The B2D mice likely display lower energy expenditure (estimated from lower O2 consumption), lower activity, and similar food intake, but are leaner. The question is why? What is then the role of FAD for energy balance? Importantly, does B2D induce lipodystrophy in a manner similar to IEMs?</p></disp-quote><p>Our findings show that B2D lowers energy expenditure and reduces body weight but we were unable to detect changes in food intake.</p><p>To our knowledge, almost no studies explored the requirements for FAD in energy balance in a comprehensive, mechanistic way. This lack of attention to a critical electron transfer cofactor and regulator of diverse flavoproteins motivated our study. We also searched extensively for energy expenditure analysis of animal models and people of IEMs resembling B2D. Only a handful of studies addressed the issue. IEMs that arise from mutations in genes encoding mitochondrial FAD transfer enzymes for FAO are often identified by ectopic fat distribution and liver disease (J Inherit Metab Dis 42:608–619, 2019). People with long-chain fatty acid oxidation disorders (LC-FAODs), including mutations in the FAD-dependent protein ACADVL, show similar energy expenditure phenotypes as B2D. Energy expenditure is significantly lower among subjects with LC-FAODs compared to the reference population in the National Health and Nutrition Examination Survey (Mol Genet Metab 138:107519, 2023). These observations suggest responses to B2D are relevant to studying IEMs defined by mutations in FAD-dependent metabolic enzymes.</p><p>In new efforts to explore energy balance in this model, we examined markers of thermogenesis. Control diet and B2D showed similar brown adipose tissue (BAT) morphology and gene expression patterns (Supplemental Figure 3). Overall our results show that B2D causes an energy conservation phenotype with reduced energy expenditure. It remains unclear whether this is a primary or compensatory change in response to B2D. We have clarified this point in the discussion.</p><disp-quote content-type="editor-comment"><p>3: I highly recommend the authors subject the mice to metabolic cages during the first 2 weeks of the diet when body weights are still identical between groups, rather than after 4 weeks of the diet. According to PMID:22205519, once obesity or leanness has developed, behavioral and metabolic alterations triggered by the body weight change may obscure or confound the processes that caused the changes in body weight and/or body composition in the first place. Thus, assessing body weight and body composition phenotypes requires a careful analysis of the various factors that might affect these phenotypes. If changes in caloric intake or energy expenditure are observed before the change in body weight or fat mass, it is more likely that one can attribute the difference to these changes.</p></disp-quote><p>We agree that body weight changes represent complex outcomes that require careful analysis. In our studies, we follow the most contemporary analysis protocols, including the use of CalR (Cell Metab 2018, 28:656-666) to determine whether energy expenditure variables change as a result of the diet. For this phenotype, body mass variables (without normalization to lean body mass) were accounted for in our statistical analyses to report the energy expenditure data accurately. We cannot find other reported mouse models of IEM where energy expenditure was analyzed by CalR to identify body-weight independent effects. As we now discuss in the manuscript (revised Discussion section), we note that B2D effects resemble energy expenditure measurements for people with IEM (Mol Genet Metab 138:107519, 2023). To further address the reviewer's concern, we performed measurements of food intake during the first week of B2D (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). One week of B2D did not impact food intake. We know additional experiments and equipment time will be needed to address the complex energy balance effects of B2D, and this will be the focus of our future work.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>One-week of B2D does not affect food intake or ad libitum blood glucose.</title><p>Individually housed one-month old male mice (n=3 per group) were exposed to 99% B2D or isocaloric control diet (Ctrl) for one week. (a) Cumulative food intake. (b) ad libitum blood glucose. Data are represented as mean +/- SEM. Mann-Whitney test for a and b.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84077-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>4. As mammals cannot synthesize vitamin B2 and diet remains the only available source of FAD, why reducing vitamin B2 in the diet by 90% does not impact liver FAD levels nor influence energy balance (Figure S1)? How do the mice adapt to a 90% reduction in vitamin B2 intake? Is a 90% reduction enough to monitor the complete metabolic phenotype of vitamin B12 deficiency?</p></disp-quote><p>Our results show that three weeks of 90% B2D did not influence whole-body metabolic phenotypes. Based on data reported by Fenton and Cowgill (J Nutr 34:273–283, 1947), mice require about 4 mg riboflavin/kg diet for normal growth. This level varies among mouse strains. However, mouse chow generally contains 6 or 7 mg riboflavin/kg diet (American Institute of Nutrition, 1977). Most tissues store very little of the vitamin as riboflavin. The majority of bioavailable riboflavin is converted to FAD and excess is excreted in urine as FMN (N Engl J Med 283:463-472, 1970). Riboflavin turnover rates in rodents are also relatively slow at approximately 16 days (J Nutr 93:445-453, 1967), which underscores sufficient FAD concentrations remain in the liver after four weeks of 90% B2D. Therefore, the historical literature suggests 10% of the required level of riboflavin may be sufficient for growth and metabolism in the mouse in our four week monitoring period. In our revision, we expanded our comments on the riboflavin requirements to support mouse body weight gain and placed our observations within the nutritional studies performed almost 80 years ago. We are unaware whether the riboflavin requirements for C57BL/6 mice have ever been revisited.</p><disp-quote content-type="editor-comment"><p>5. The authors state that FAD is required for hepatic glucose production during fasting. However, the data presented in Figure 2a show that liver FAD displays the opposite 24-h rhythm to liver glucose. It is not ideal to show hepatic glucose level, as the liver secrete glucose into the circulation. The authors should instead plot the 24-h rhythm of fed/fasted liver FAD levels and the corresponding fed/fasted blood glucose levels. According to previous publications, liver FAD levels usually coincide with blood glucose.</p></disp-quote><p>Thank you for the excellent suggestion. Revised Figure 2 includes liver FAD levels in the fasted and re-fed state, which demonstrates liver FAD levels coincide with blood glucose levels.</p><disp-quote content-type="editor-comment"><p>6. Authors normalized relative abundances/fold changes from metabolomics measurements to tissue weight. Normalization to the total protein level would be more suitable.</p></disp-quote><p>We have extensively compared metabolomic data normalized to total DNA, total protein, tissue weight, and total signal, and we’ve found that total DNA, tissue weight, and total signal all perform equally well and better than total protein. The problem with total protein is that it cannot be measured accurately after metabolite extraction, whereas total DNA, tissue weight, and total signal can all be measured accurately after metabolite extraction. Our previous publication (Anal Chem 85:9536-9542, 2013) laid the groundwork for accurate metabolomic data normalization, and over the past ten years since that publication we’ve optimized protocols for accurate measurement of tissue weight and found the approach yields reproducible results.</p><disp-quote content-type="editor-comment"><p>7. In Figure 4b, it is surprising to observe that the body weights of the mice are significantly different at week 0 before any diet interventions. The authors should provide an explanation for this data. This is in fact different from the data presented in Figure 1d (data shown in % for some reason). Another question is why this experiment used 9 weeks of diet while other experiments used 4 weeks of diet. Figure 1d, and Figure 3d showed % weight change during the 4 weeks of diet, and absolute body weights should also be shown during the 4 weeks as shown in Figure 4b. Consistency in presenting the data would help in comparing the results of different experiments.</p></disp-quote><p>Thank you for pointing this out. Body weight % measurements equalize the average weight of the two groups before treatment, enabling a clear graphical depiction of the change elicited by the interventions from the same starting point. Nonetheless, we acknowledge the previous representation of body weight change may cause confusion. Animals were randomly assigned to control or B2D and we did not attempt to match initial body weights, therefore any differences in initial body weight occurred by chance. In the process of re-assessing the statistics for Figure 4D, we do not find body weights are different at week 0 or week 1. To that end, we revised all figures to show body weight (g) and body weight gain (%) for all experiments to facilitate comparison of the results of the different experiments.</p><p>Regarding the experimental design, we exposed mice to B2D long enough to durably establish steady-state weight gain effects before fenofibrate exposure. We used malnutrition (J Hepatol 65:1198-1208, 2016), Ppara knockout (Gut 65:1202-1214, 2016), cancer cachexia (Proc Natl Acad Sci USA 115: E743–E752, 2018), and other riboflavin-depletion studies (Ann Neurol 84:659-673, 2018) as guides to design the B2D experiments and fenofibrate interventions. The revised methods section cites these studies.</p><disp-quote content-type="editor-comment"><p>8. Figure 5d shows a representative protein blotted for each complex (Total OXPHOS Rodent WB Antibody Cocktail, ab110413), which unfortunately does not represent the whole complex. Thus, the authors cannot conclude that B2D and fenofibrate lacked meaningful impacts on relative levels of oxidative phosphorylation proteins. It would be surprising that, if PPARa activity is impacted, some genes encoding various subunits of these complexes would not change as many are known as direct targets of PPARa.</p></disp-quote><p>We agree and edited the text accordingly to note the OXPHOS antibody only detects a fraction of mitochondrial proteins. In the discussion, we noted that fibrates show a minor impact on OXPHOS complexes only at high concentrations compared to other lipid and glucose lowering agents, such as statins and thiazolidinediones (Toxicol Appl Pharmacol 223: 277-287, 2007).</p><disp-quote content-type="editor-comment"><p>9. For the heatmaps shown in Figure 6a, 6d, the authors compared Ctrl vs B2D, and Ctrl FF vs B2D FF individually, with no comparison between -FF and +FF groups because they are not comparable considering the different lengths of diet (4 weeks vs. 9 weeks) and no placebo gavage for the -FF group. Nonetheless, the authors compared 4 groups together in Figure 5a, 5b, 5c, 5d, 5e, and 6e. Are they different samples? If not, this analysis is flawed.</p></disp-quote><p>We appreciate your input. Although the diet treatments are different, we feel inclusion of these contrasts remains important for the study. The fenofibrate treatments uncover new gene and metabolic programs beyond B2D alone, including greater activation of the integrated stress response. The text and figure legends have been revised to clarify sampling times for these experiments. To perform new experiments and associated mass spectrometry analysis, we would need to repeat experiments on four additional groups of mice and home in on appropriate times for sampling. This is non-trivial and beyond the scope of the current project.</p><disp-quote content-type="editor-comment"><p>10. In Figure 2b, the authors perform an &quot;HGP&quot; (hepatic glucose production). However, in the methods, they state that they inject radioactive glucose, and then measure plasma glucose. This experiment would test glucose consumption and not production. Next to this panel, there is a pyruvate tolerance test which is the correct experiment. Is (a) the HGP experimental methods a typo and they actually used radioactive pyruvate? Or did they (b) actually measure glucose consumption by injecting radioactive glucose? If (a), please correct this typo. If (b), test glucose production by injecting radioactive pyruvate rather than radioactive glucose if possible.</p></disp-quote><p>We clarified the description of the glucose metabolism data in Figure 2 and separated the pyruvate tolerance test and the hepatic glucose production panels. Our lab performed studies of infused (not injected) radiolabeled glucose to assess basal hepatic glucose production at steady state. The revised Materials and methods includes additional details of the protocol. Additional details regarding the protocol can be found at the MMPC: https://www.mmpc.org/shared/document.aspx?id=137&amp;docType=Protocol.</p></body></sub-article></article>